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Up to one third of patients with schizophrenia show only limited response to 
dopamine blocking antipsychotic medication. This could be due to distinct 
neurobiological abnormalities in this subgroup of patients.  While there is robust 
evidence to suggest that the neurobiology of schizophrenia involves increased 
presynaptic striatal dopaminergic elevation, little is known as to whether this 
abnormality is present in treatment resistance, and consequently the 
relationship between this dopamine abnormality and the lack of response to 
treatment remains unknown.  Furthermore, it remains unclear whether 
treatment resistance manifests at the outset of illness, and perhaps has a 
neurodevelopmental origin, or whether it evolves over time, possibly as a result 
of a neurodegenerative process.   
 
The first study in this thesis investigated striatal presynaptic dopamine synthesis 
in twelve treatment resistant schizophrenic patients, twelve patients with 
schizophrenia who had responded to antipsychotics, and twelve healthy 
volunteers, using [18F]-DOPA  Positron Emission Tomography (PET).  Thus, it 
was possible to test the hypothesis that the response to treatment is determined 
by differences in presynaptic dopamine function.  The results demonstrated that 
there were no significant differences in striatal dopamine synthesis capacity 
between treatment resistant patients and healthy volunteers, whilst dopamine 
synthesis capacity was significantly increased in responders relative to 
treatment resistant patients.  The difference was most marked in the associative 





A second, large follow-up study of first episode psychosis (FEP) patients, 
examined the course of treatment resistance over the 10 year follow up.  It was 
found that over 80% of treatment resistant patients were persistently resistant 
from the initiation of antipsychotic treatment.  My PET study, due to its cross 
sectional design, could not determine whether the normal dopamine levels 
predate the antipsychotic exposure in treatment resistant patients.  However, by 
demonstrating that a great majority of treatment resistant patients are resistant 
to dopamine blocking antipsychotics at first ever initiation of treatment, my 
second study raises the possibility that these patients may have had normal 
dopamine levels even at the outset of their psychotic illness.   In the same FEP 
cohort it was possible to investigate neurodevelopmental predictors of treatment 
resistance. The finding that the negative symptom dimension and younger age 
of onset were significant predictors of treatment resistance is compatible with 
the view that TRS may be of neurodevelopmental origin. 
 
Overall, my observations in this thesis indicate that TRS may be a distinct and 
enduring subtype of schizophrenic illness of a possible neurodevelopmental 
origin whose pathophysiology is not marked by alterations in dopamine 
synthesis capacity.  Findings emerging from this thesis provide a platform for 
future studies, which may lead to the discovery of much needed new treatments 
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Chapter 1  Introduction 
 
1.1 Clinical Subtypes of Schizophrenia 
Since its conception, schizophrenia has been described in terms of distinct 
clinical subtypes.  However, the adequacy of this categorical approach, which 
till recently formed the basis of modern descriptive systems of psychosis, such 
as those in the ICD-10 and the DSM-IV, has been criticized for its failure to 
adequately capture the rich and heterogeneous psychopathology of the 
disorder (Demjaha et al., 2009).   Following the DSM-V revision, the categorical 
subtypes of schizophrenia (paranoid, disorganized, catatonic, and 
undifferentiated) were removed, and instead the use of psychopathological 
dimensions that provide the more useful description of psychotic patients is 
encouraged in an appendix (Tandon et al., 2013).  
 
Nevertheless, the modern diagnostic systems continue to ignore the important 
subtyping based on treatment response, despite the knowledge that the former 
diagnostic subtypes were not a good predictor of future response to 
antipsychotics (Bromet et al., 2011).  Although not formally operationalized, the 
clinically highly relevant sub-entity of schizophrenia: “Treatment Resistance,” is 
clearly delineated, both in terms of criteria and specific treatment. However, the 
important question of whether treatment resistant schizophrenia (TRS) is 





1.2 Treatment resistant schizophrenia 
Schizophrenia is a severe and often incapacitating mental disorder with an 
average life-time prevalence of about 0.5 to 1.0 percent of the population 
worldwide, and contributes considerably to the global burden of disease 
(Murray and Lopez, 1997; Rossler et al., 2005) with a 2- to 3-fold increase in 
mortality risk compared with the general population (Saha et al., 2007).  The 
fortuitous discovery of Chlorpromazine, more than a half a century ago (Delay 
et al., 1952), brought new treatment hopes and  prognostic improvement 
(Creese et al., 1976). However, despite considerable scientific and therapeutic 
progress, up to one third of patients (Lindenmayer, 2000) continue to 
experience distressing delusions, hallucinations, thought disturbances and 
functional impairment.  Treatment resistance in this condition is one of the 
greatest therapeutic challenges to psychiatry, significantly affecting patients, 
their families and society in general. Improved understanding of the 
neurobiology of schizophrenia is prerequisite to successful treatment; therefore 
identification of a precise molecular abnormality, particularly in patients who fail 
to respond to available treatment is of utmost clinical importance.  Whilst there 
is sufficient evidence to suggest that the neurobiology of schizophrenia involves 
presynaptic striatal dopaminergic elevation (Fusar-Poli and Meyer-Lindenberg, 
2012; Howes et al., 2012),  little is known as to whether this abnormality is 
present in patients resistant to antipsychotic treatment.  Consequently, the 
reasons for this non-response remain elusive, which poses a considerable 
constraint on developing novel and much needed neurobiologically determined 
treatments.  It is clear, however, that treatment resistance to dopamine blocking 




hypothesis in that the theory fails to explain the refractory nature of some cases 
of schizophrenia.  This failure is highlighted by the fact that clozapine, the only 
antipsychotic to date that is effective in majority of those who fail to respond to 
conventional antipsychotics (Taylor and Duncan-McConnell, 2000), is only a 
weak D2 blocker, and some think, it exerts its therapeutic effect via 
mechanisms involving other neurotransmitters such as glutamate or serotonin 
(Gellman and Aghajanian, 1994; Javitt, 2004; Tanahashi et al., 2012).   
 
1.3 Neurobiology of schizophrenia 
1.3.1 Dopamine Hypothesis 
 
The DA hypothesis heuristically survives as one of the most eminent theories of 
schizophrenia, reputed to play a principal role in explaining the neurobiological 
mechanisms of this complex disorder.  Its principles lie in Arvid Carlsson’s 
seminal work which showed that the administration of chlorpromazine and 
haloperidol stimulated the turnover of DA in the brains of mice (Carlsson and 
Lindqvist, 1963). The hypothesis claims that subcortical hyperdopaminergia 
contributes to the positive psychotic symptoms, which may explain the success 
of dopaminergic blocking drugs in alleviating these symptoms.  And indeed, the 
DA hypothesis received support from pharmacological evidence indicating that 
the efficacy of antipsychotic drugs is related to DA D2 receptor blockade, 
beginning with observations that the relative clinical potencies of antipsychotic 
drugs closely parallels their affinity to bind and block the DA D2 receptor 
subtype (Creese et al., 1976b; Seeman et al., 1976).  Additional support for a 




amphetamine, can lead to psychosis as well as that many patients with 
schizophrenia experience worsening of symptoms following acute exposure to 
amphetamines (Connell, 1958). 
 
Later, the original DA hypothesis was revised to account for the neurobiology of 
negative and cognitive symptoms (Davis et al.,1991), suggesting that these 
symptoms are related to a deficit in cortical DA transmission. Therefore, the 
revised version incorporates both the subcortical hyperdopaminergia and frontal 
hypodopaminergia, and their co-existence in schizophrenic patients has been 
subsequently supported by several PET and Single Photon Emission Computed 
Tomography (SPECT) studies (Abi-Dargham et al., 2002; Abi-Dargham, 2004). 
Evidence from animal studies offers a molecular explanation for the 
mechanism, suggesting that frontal hypodopaminergia results in increased 
levels of DA in the striatum. However, there is also evidence to suggest that 
prefrontal cortical function can be impaired by increased dopamine D2 receptor 
expression in the striatum (Kellendonk et al., 2006).  More recent modifications 
of the DA hypothesis took into account DA's important roles in learning and 
motivation to further explain positive symptoms of schizophrenia.  In line with 
this, Gray et al., (1991) suggested that coincident events are regarded as highly 
salient in states of hyperactive DA signalling.  These ideas have evolved further 
to propose that elevated dopaminergic neurotransmission leads to increased 
salience being assigned to insignificant events or normal external and internal 
stimuli, and this in turn is responsible for genesis of psychosis (Kapur, 2003; 





1.4 Imaging the DA system 
In the last two decades, by using neurochemical imaging techniques such as 
PET and SPECT, it has been possible to obtain direct evidence of enhanced 
dopamine transmission in a living human brain.  PET and SPECT studies 
indicated that multiple aspects of dopaminergic transmission, specifically 
increased DA D2 receptor occupancy, increased DA release and elevated DA 
synthesis, may cause dopaminergic overactivity that is responsible for symptom 
formation in schizophrenia.  The emphasis of the research in this field was 
mainly on the striatum, given that it is highly populated by D2 receptors and has 
rich dopaminergic projections and connections with other brain areas, 
particularly with the thalamus, ventral tegmental area (VTA), and the septo-
hippocampal system. Striatum is not uniform histologically, and can be 
functionally divided, on the basis of differential striatal-cortical connectivity, into 
limbic (LST), associative (AST), and sensorimotor (SMST) subdivisions, along 
the dorsolateral to ventromedial gradient (Martinez et al., 2003; Joel et al., 
2000).  These subdivisions are equivalent to anatomical substructures and 
functionally relate to emotion, reward mechanisms, motor and cognitive 
processes (Huber et al., 1975; Martinez et al., 2003). Thus, LST is involved in 
reward, motivation and emotional regulation, AST processes cognitive 
information, and SMST is concerned with sensorimotor processing (Figure1.1).  
Anatomical equivalents, projections and related functions are presented in 












Summary diagram illustrating striatal functional subdivisions (LST, AST, and SMST) 
based on inputs from specific cortical, thalamic, and midbrain regions.  LST receives 
input from limbic structures, AST from associative cortical regions and the dorsolateral 




































































1.4.1 DA D2 receptors occupancy in schizophrenia 
 
Striatal DA D2 receptors have received much attention and have been 
investigated extensively in recent decades in schizophrenia studies, which is 
not surprising given the fact that they are a principle target of antipsychotic    
medication. DA D2 were the first neuroreceptors that were imaged by PET and 
SPECT scanning that permitted their visualization in vivo (Wagner et al., 1983), 
using a variety of radiotracers, most commonly 11C Raclopride, 11C N-
methylspiperone and [123I]IBZM. 
 
Molecular imaging studies observed alterations in DA D2/D3 receptors, 
however the results were conflicting (Farde et al.,1995), which was largely 
attributable to the effects that chronic exposure to antipsychotics has on DA 
receptor up-regulation. Meta-analytic work of molecular imaging studies 
(Laruelle, 1998; Zakzanis and Hansen, 1998) revealed much smaller increase 
in DA D2 receptors than that observed in early post-mortem studies, confirming 
the confounding effect of exposure to antipsychotic medication, that was not 
possible to account for in post-mortem status. However, in a subsequent meta-
analysis (Weinberger and Laruelle, 2002), a modest (12 percent), yet significant 
increase in DA D2 receptors was confirmed in drug naive patients with 
schizophrenia compared to healthy controls.   
 
Contrary to this, the most recent meta-analysis showed no increase in DA D2/3 
receptor availability in drug-naive patients, although an elevation of small effect 
size (Cohen d = 0.26) in previously medicated patients was observed (Howes et 




by using α-methyl para-tyrosine (AMPT), which blocks tyrosine hydroxylase and 
thus prevents new DA synthesis, have demonstrated increased DA D2 receptor 
occupancy in schizophrenic patients compared to controls (Abi-Dargham et al., 
2000).  Intriguingly, one study demonstrated that DA D2 receptor levels are 
elevated in healthy monozygotic co-twins compared to dizygotic co-twins of 
twins with schizophrenia, which may suggest that DA D2 receptor up-regulation 
confers a genetic risk (Hirvonen, 2005). 
 
Most imaging studies of DA D1 receptors have observed no abnormalities of 
striatal DA D1 receptors in schizophrenic patients (Abi-Dargham et al., 2000; 
Karlsson et al., 2002 et al; Okubo et al., 1997).  However, in the pre-frontal 
cortex of drug-naïve patients one study reported no change (Karlsson et al., 
2002), one study reported decreased levels (Okubo et al., 1997), and two 
others reported increases (Abi-Dargham et al., 2012; Abi-Dargham et al., 2002).  
 
On the whole, despite extensive research, although it is possible that a small 
DA D2 receptor elevation is present in brains of drug-naïve schizophrenic 
patients, the evidence remains equivocal and mostly unconvincing, which, as 
examined by Weinberger and Laruelle, (2002), is a consequence of 
underpowered studies, imaging protocol, or sampling effects that may have 








1.4.2 Increased DA release  
 
In contrast to DA receptor studies, the evidence of increased dopamine release 
in schizophrenia has been more consistent and robust. The principle underlying 
an excessive amphetamine-induced dopamine release technique is based on 
endogenous competition between the released dopamine and the radiotracers 
for binding to DA D2 receptors, which reduces radiotracer binding; this then 
provides an indirect index of released dopamine.  In these studies, brain scans 
are performed twice, before and after amphetamine challenge, and the 
difference between these two scans reflects the amount of DA release following 
the challenge.  
 
Both PET and SPECT studies that have used this paradigm have shown similar 
results, demonstrating an excessive amphetamine-induced dopamine release 
by reporting approximately doubled radiotracer displacement in patients with 
schizophrenia compared with controls (Abi-Dargham et al., 1998; Breier et al., 
1997; Kestler et al., 2001; Laruelle et al., 1996; Laruelle and Abi-Dargham, 
1999).  Furthermore, enhanced DA release was associated with increased 
positive symptoms (Laruelle et al., 1996).  However, although evident even at 
the onset of illness, or during acute relapses or exacerbation, excessive release 
has not been associated with remission status (Laruelle et al., 1999).     
 
1.4.3 Increased presynaptic DA synthesis capacity 
 
   
The most widely used tracer for measuring presynaptic DA synthesis is [18F]-




vesicles in areas rich in Aromatic Amino Acid Decarboxylase (AAADC), such as 
the striatum. This accumulation reflects DOPA uptake and conversion to DA, 
quantified as the influx constant Ki, that parallels decarboxylase activity, giving 
an indication of the DA synthesis capacity in the presynaptic terminals of 
striatal dopaminergic neurons (Moore, 2003).  The biochemistry of DA 
synthesis is presented in a schematic diagram (Figure 1.2). 
 
PET derived evidence indicates that a dysfunction of the presynaptic striatal DA 
system may be a critical factor in developing schizophrenia.  At present this 
neurochemical abnormality constitutes the most replicated, robust finding in 
dopaminergic studies in schizophrenia (Howes and Kapur, 2009), which is 
confirmed in two recent meta-analyses (Fusar-Poli & Meyer-Lindenberg 2012; 
Howes et al., 2012). Howes and colleagues (2012) examined all aspects of 
presynaptic DA transmission (DA synthesis capacity, synaptic DA levels, and 
DA release) and reported a highly significant increase in presynaptic function 
with a large effect size of 0.79.  Fusar-Poli & Meyer-Lindenberg (2012) focused 
solely on studies that examined DA synthesis capacity.  The meta-analysis of 
11 PET studies comprising collectively 113 subjects and 131 healthy volunteers 
(Table 1.2), revealed 14 % elevation in dopamine synthesis capacity in patients 
with schizophrenia.   
 
All the studies that reported increased DA synthesis involved acutely psychotic 
patients. The three remaining studies, of which one reported decreased [18F] -
DOPA synthesis (Elkashef et al., 2000) and 2 others observed no significant 




patients who were relatively symptom free at the time of scanning.  
Interestingly, studies involving medication free/naïve subjects have reported 
elevated DA synthesis suggesting that medication cannot explain the elevation 
seen in these patients. Three positive studies included first-episode psychosis 
patients (Hietala et al., 1995; Hietala et al., 1999; Lindstrom et al., 1999).  
Furthermore, increased DA synthesis capacity has been demonstrated even in 
individuals who are at high risk of developing schizophrenia thus indicating that 
this dopaminergic abnormality predates the onset of frank psychosis (Howes et 
al., 2009), and progressively increases in those who go on to develop psychotic 





















 Figure 1.2 Schematic presentation of presynaptic DA regulation 
 
 
Conversion of L-tyrosine (4-hydroxyphenylalanin) to L-3, 4 dihydroxyphenylalanine [L-
DOPA] constitutes the first step in a complex pathway of dopamine synthesis. L-
tyrosine is derived mainly from dietary sources, although a small quantity originates 
from L-Phenylalanine converted to L-tyrosine by phenylalanine hydroxylase (PHA). L-
tyrosine is converted to L-DOPA by tyrosine hydroxylase (TH).  AAADC then acts on L-
DOPA to convert it to DA. The DA uptake transporter (DAT) plays an additional role in 
increasing cytoplasmic DA levels via the reuptake of extracellular DA and thus 
maintains extracellular dopamine homeostasis.  From the cytoplasm the majority of DA 
is stored in specialized synaptic vesicles by the vesicular monoamine transporter 




   
































      
   
   


































































































































































































































   






































   

































































































































   







































































1.5 The role of other neurotransmitters in neurobiology 
of schizophrenia 
          
Although increased presynaptic dopamine synthesis has been documented in 
most PET studies, and as such, it constitutes the most replicated and robust 
finding in dopaminergic studies in schizophrenia, there is an overlap in 
dopamine synthesis capacity between patients and healthy subjects (Hietala et 
al., 1999; McGowan et al., 2004), where values in some patients are observed 
to be within the normal range.  This observation suggests that dopamine 
dysfunction may not be the only abnormality in all patients with schizophrenia, 
and that the pathophysiology of such a complex disorder may involve 
aberrations in other neurotransmitters (Carlsson et al., 2001).  
 
Among other neurotransmitters, glutamate has received particular attention in 
recent decades (Coyle et al., 2003; Kim et al., 1980; Tamminga, 1998) due to 
the psychogenic effects of phencyclidine (“angel dust”) or ketamine, that  are 
powerful non-competitive antagonists of the N-methyl-d-aspartate (NMDA) 
glutamate receptor (Lodge and Johnson, 1990), and can precipitate relapse in 
remitted patients (Cohen et al., 1962).  Furthermore, glutamate may impact 
differentially to DA on schizophrenic symptomatology and be more accountable  
for negative symptoms (Stone et al., 2007), which is of clinical significance, 
specifically in terms of new drug developments.  
 
DA, glutamate and Gamma-Aminobutyric Acid (GABA) interactions in complex 
neurocircuits are hypothesized to be of particular importance for psychosis 




postulated that the dysfunction in cortical systems involving glutamate and 
GABA neurotransmission may be responsible for the pathophysiology of 
schizophrenia (Grace, 2000; Lewis et al., 1999). Carlsson and colleagues 
hypothesized that cortical hypoglutamatergia, either acting directly as an 
“accelerator” or via GABA interneurons projections, as a “brake,” modulates the 
firing of dopaminergic neurons that can in turn lead to either decrease or 
increase in dopaminergic activity (Figure 1.3).  Thus, for instance, the reduced 
glutamate activity enhances DA release in dopaminergic pathways, which then 
via negative feedback, mediated, at least in part, via the striatum and the 
thalamus, regulates glutamate release that would then act as “a brake” on 
cortical DA production (Carlsson et al., 2000; Carlsson et al., 2001; Stone et al., 
2007).  
 
Figure 1.3 Hypothetical cortical glutamate and GABA mediated regulation 







Abnormalities in both GABA and serotonin (5-HT) transmission in 
schizophrenia have also been observed. GABA is widely distributed and the 
principal inhibitory neurotransmiter in the brain.  The deficiency of GABAergic 
interneurons in the prefrontal cortex and hippocampus has been consistently 
reported in both preclinical and in vivo studies (Bussato et al., 1997; Lewis et 
al., 1999; Perry et al., 1997; Reynolds et al., 2001).  However, contrary to these 
findings and subsequent expectations, GABA agonists have not proved to be 
effective in treatment of schizophrenia or have shown relatively low effect, 
which suggests that perhaps the inhibitory deficiency is not directly related to 
GABA in patients with schizophrenia (Taylor D., 2006).  
  
Findings regarding serotonergic abnormalities are less consistent. The support 
for serotonin involvement in schizophrenia was derived from the observations 
that LSD induces a psychotic state characterized by visual hallucinations.  LSD, 
similarly to newer atypical antipsychotics, has a specific affinity for serotonin 
receptors, particularly 5-HT2A subtype (Glennon et al., 1983, Taylor D; 2006).  
The fact that clozapine exerts antagonistic effect at the 5-HT2 receptor 
(Lieberman et al., 1998), and is effective where higher affinity DA blockers fail, 
gave additional support to serotonin model and DA-Serotonin hypothesis of 
schizophrenia (Meltzer et al., 1989).  Since clozapine has a much higher affinity 
for the DA D4 than for the DA D2 receptor, combined DA D4 and 5-HT2 
receptor antagonism seemed of particular significance in the treatment of 
schizophrenia. However, fananserin, a potent antagonist at these two 
receptors, was demonstrated to be ineffective for schizophrenic symptoms 




selective 5-HT2A antagonist, has been shown in some studies to have 
antipsychotic efficacy, although the evidence was inconclusive and it has not 
been approved for the use in treatment of schizophrenia (Meltzer and Nash 
1991). The majority of post-mortem studies reported increase in 5-HT2A 
receptor density in the prefrontal cortex (PFC) (Abi-Dargham, 2007), however 
in vivo studies were less convincing.  Thus, Lewis et al., (1999) in their PET 
study failed to confirm the reduction in 5-HT2 receptors found in postmortem 
studies of schizophrenia and concluded that serotonergic abnormality in 
schizophrenia, if at all present, is unlikely to be associated with the 5-HT2 
receptors.  
 
Overall, these neurotransmitters are both anatomically and functionally 
interconnected, and the emerging evidence suggests that they all contribute to 
the pathogenesis of schizophrenia, although knowledge of precise mechanisms 
of their interplay in schizophrenia is currently lacking. It has been suggested 
that the schizophrenic pathophysiology may not even involve these 
neurotransmitters directly, but could be related instead to general connectivity 
defects that may originate from the disrupted neurodevelopment (Carlsson et 
al., 2001, Weinberger, 1995; Weinberger, 1987).    
 
1.6 Neurobiology of treatment resistance 
Little is known about the neurobiology of treatment resistance in schizophrenia. 
There is some evidence from magnetic resonance imaging (MRI) studies that 
patients who show limited response to treatment have increased cortical 




These findings are confirmed in a recent MRI study conducted in 25 responders 
and 14 non-responders experiencing first episode psychosis.  The authors 
reported increased cortical thickness in responders, which was also associated 
with more rapid response (Szeszko et al., 2012).  However, these studies may 
have been confounded by the reported effects of antipsychotics on cortical 
volume (Moncrieff, 2011). Dorph-Petersen and colleagues (2005) observed an 
8–11% reduction in mean fresh brain weights of macaque monkeys that were 
chronically exposed to olanzapine and haloperidol. Subsequently Ho et al., 
(2011) confirmed in their large FEP longitudinal study that antipsychotic 
treatment had a significant influence on brain volumes of these patients.  More 
recently, Zipursky and Murray (2013) reported that some of the decreases in 
brain tissue volumes are explainable by the effects of antipsychotic medication. 
 
PET studies have demonstrated a significant association between striatal DA 
D2 occupancy and prediction of short-term clinical response to antipsychotic 
treatment (Kapur et al., 2000), and have indicated that at least 60%  of DA D2 
receptor occupancy is necessary to achieve clinical response to antipsychotic 
treatment, which has been shown with both typical antipsychotics (Kapur et al., 
2000; Nordstrom et al.,1993) and atypical antipsychotics (Abi-Dargham & 
Laruelle, 2005; Zipursky et al., 2005), excluding clozapine that shows lower DA 
D2 occupancy (Nordstrom et al., 1995).   In line with this, Wolkin et al., (1989) 
using PET examined DA D2 receptor occupancy in 10 treatment resistant 
schizophrenics, hypothesizing that the lack of response in these patients may 
result from inadequate DA D2 receptor blockade.  However, almost identical 




were observed (Wolkin et al., 1989).  Correspondingly, a [123I] IBZM Single 
Photon Emission Tomography (SPET) study conducted on 10 responders and 8 
non-responders reported a similar degree of DA D2 occupancy in both groups 
(Pilowsky et al., 1993).  Moreover, in a third study that examined DA D2 
occupancy in six medicated patients with chronic schizophrenia using PET 
radiotracer, [11C]-methylspiperone, more than 95% DA D2 occupancy was 
demonstrated (Coppens et al., 1991).  Intriguingly, Kane et al., (1988) in their 
seminal trial included the most severely ill and treatment resistant patients with 
schizophrenia who failed a prospective trial of haloperidol at doses of at least 
60mg/day, which indirectly suggests that DA receptor occupancy was 
sufficiently achieved. 
These findings imply that whilst adequate DA D2 blockade may be necessary, 
it is not sufficient in all cases and does not guarantee a response. Notably, 
differential blockade does not seem to explain the mechanisms of treatment 
resistance to dopaminergic blocking antipsychotics.  
 
There is, however, some evidence to suggest that presynaptic dopaminergic 
elevation instead may be linked to treatment response. Abi-Dargham and 
colleagues found that higher synaptic DA levels, as measured using DA 
depletion paradigms, were associated with a better response to antipsychotic 
treatment (Abi-Dargham et al., 2000).  Furthermore, studies that examined 
dopamine metabolites in relation to antipsychotic response have reported 
higher pre-treatment plasma homovanillic acid (pHVA) in responders compared 
to treatment resistant patients (Chang et al., 1990; Duncan et al., 1993), and 




cerebrospinal fluid (Van Kammen and Schooler, 1990).  Thus the available 
evidence raises an important question of whether in treatment resistance: a) 
dopaminergic dysfunction is not a primary abnormality b) or, is such that 
antipsychotics fail to adequately normalize its activity. However, to date no 
study has examined DA synthesis capacity in vivo in specifically treatment 
resistant patients and the relevant question whether this abnormality is present 









1.7 Clinical course and predictors of TRS 
 
1.7.1 The course of TRS  
  
Another question that remains unanswered is whether TRS manifests right at 
the onset of psychosis or evolves over time as a result of perhaps 
neurodegeneration or neurochemical sensitization.  At the beginning of the last 
century, Kraepelin, referring in his textbook to Albrecht’s observations that one 
third of his cases with hebephrenia reached terminal state within a year of 
onset, concluded: “Often enough the unmistakable symptoms of dementia 
appear already within the first year” (Kraepelin, 1919), citing, in addition, several 
other similar findings by experienced psychiatrists at the time. Thus, even prior 
to modern psychopharmacology, there were reports to suggest that bad 
outcome may identify a distinct and enduring subtype of schizophrenic illness, 
one that is perhaps more severe and of neurodevelopmental origin (Lieberman 
et al., 1997). 
  
Considering the other possibility, that a proportion of patients become less 
responsive to pharmacological treatment as the illness progresses, Kolakowska 
and colleagues (Kolakowska et al., 1985) examined retrospective accounts of  
medicated patients 2 - 20 years after their first presentation.  However, the 
authors found that majority of 40 poor responders in their sample were 
unresponsive throughout the illness, and thus concluded that treatment 
response is related to the type and not the stage of illness. The main 
methodological limitation of this study is the retrospective examination of clinical 




examination of medical records could have lead to a measurement error 
(Rothman et al., 1987). Still, as the authors rightly state, the bias would be 
towards “over-estimation” of remission particularly if there was no association 
with gross behavioural disturbances.  In addition, previous longitudinal studies 
have similarly observed that a type of illness course is apparent in early stages 
of illness, thus supporting this notion (Bleuler M, 1978; Huber et al., 1975).  
 
However, Wyatt (1991) reviewed the evidence derived from twenty two studies 
of predominantly FEP patients, that examined the effect of medication on the 
natural course of schizophrenia, suggested that early psychopharmacological 
intervention improves the outcome and prognosis of illness.  They proposed 
that a neurodegenerative process may be inherent to psychosis and thus 
unfavourably affect the clinical course in those who are non-compliant and 
subjected to multiple relapses. Numerous MRI studies have subsequently 
addressed this question, but no clear support for the hypothesis has been found 
(Zipursky et al., 2012).   
 
On the other hand, there is evidence from animal studies that chronic treatment 
with DA blocking antipsychotics induces DA D2 receptor up-regulation, which in 
turn can lead to breakthrough dopamine supersensitivity and consequently 
reduce the efficacy of antipsychotic treatment despite clinically relevant levels of 
DA D2 occupancy (Ginovart et al., 2009; Samaha et al., 2007). This may imply 
that dopamine supersensitivity may predispose some patients to becoming 
resistant following repeated and long-term exposure to antipsychotic treatment.  




to remission is longer in subsequent episodes, but less, if at all, achievable 
(Lieberman, 1993; Sheitman et al., 1997).   
 
Nonetheless, still up to 20 percent of FEP patients appear to be resistant to 
medication at a very early stage of their illness, and at the time of initiation of 
treatment (Agid et al., 2011; Lieberman et al., 1996; MacMillan et al., 1986; 
Robinson et al., 1999), which cannot be explained by the effects of medication, 
neurochemical sensitization or neurodegeneration.   
 
Taken together, evidence to date raises the question of whether there may exist 
a distinct subgroup of schizophrenic patients whose pathophysiology is not 
marked by DA alterations and hence they do not derive therapeutic benefits 
from dopamine blocking antipsychotics. However, there may be another form of 
treatment resistance that indeed does develop at various stages of illness.  On 
the other hand, some treatment resistant patients may achieve spontaneous 
remission or start responding to treatment later in life (Meltzer, 1997), which is 
in line with previous observations that older schizophrenic patients require much 
less intensive maintenance antipsychotic treatment than their younger 
counterparts (Fenton WS and McGlashan MD, 1987),  and could perhaps be 
explained by the fact that DA system is age dependent, with significant 
reductions in dopaminergic transmission in older subjects being observed 











The neurodevelopmental aetiology of schizophrenia has been considered in 
some of the earliest psychiatric descriptions (Kraepelin E, 1919). The 
neurodevelopmental theory of schizophrenia proposes that early risk factors, 
present prior to the onset of psychosis, especially during the gestation period, 
interfere with normal neurodevelopment resulting in pathological aberrations 
that increase the likelihood of psychosis in early adolescence or young 
adulthood (Weinberger, 1987; Murray and Lewis 1987). 
  
More than a century ago, Clouston referred to the disorder as “developmental 
insanity” proposing that schizophrenia may be of neurodevelopmental origin 
(Clouston TS, 1891).  The idea that patients with potential neurodevelopmental 
aetiology are more likely to show poor treatment outcome has long been 
considered (Murray et al.,1992; Murray, 1994). Murray and colleagues (1992) 
hypothesized that brain aberrations in the foetal and neonatal period may give 
rise to psychotic symptoms in early adolescence, which is particularly 
associated with poor outcome. The authors suggested that “congenital 
schizophrenia” is distinguished from other forms of illness by several features 
such as obstetric complications, lower level of premorbid functioning, presence 
of a deficit state, male gender, younger onset of illness, and neurological 
alterations, which have all been linked to poor treatment response.  
Accordingly, it has been shown that a history of perinatal insults was highly 




This was subsequently confirmed in prospective first episode psychosis studies 
that found obstetric complications to be considerably more prevalent in a non-
responder group (Alvir et al., 1999; Robinson et al., 1999). Furthermore, it has 
been shown that obstetric complications are associated with ventricular 
enlargement that tends to be present at the onset of the disorder (Weinberger 
et al.,1982) which supports a neurodevelopmental model of schizophrenia 
(Cannon et al., 2002).   
 
Kolakowska and colleagues (1985) and Scottish FEP studies (Scottish 
Schizophrenia Research Group et al.,1989)  reported that most of their non-
responders were men and, in a later study, men with neurological impairment 
and prominent negative symptoms at the onset of illness were particularly at 
risk of treatment resistance.  Other studies have also reported associations of 
negative symptoms with poor treatment response (Lindenmayer et al., 2000).  
Higher prevalence of negative symptoms and their association with premorbid 
developmental impairments has been reported in adolescent schizophrenia 
(Hollis C, 2000), and additionally, prodromal negative symptoms have been 
associated with subsequent transition to psychosis (Demjaha et al., 2012), 
which potentiates their neurodevelopmental origin.  Furthermore, the deficit 
syndrome, introduced in the late eighties by Carpenter and colleagues 
(Carpenter et al., 1988) to describe primary enduring negative symptoms, is 
regarded as a distinct entity, shown to be marked by distinct neuroanatomical 





Younger age at onset has consistently been linked with poor outcome and poor 
response (Jomli et al., 2012; Mohamed, 2013), and specifically treatment 
resistance (Vanelle, 1995), which suggests an increased likelihood of early 
neurodevelopmental insults in TRS patients (McDonell and McClellan, 2007).  
 
Family history has been reported to be associated with poor prognosis of 
illness, and in addition, with negative symptoms (Malaspina et al., 2000).  Other 
neurodevelopmental factors such as severe cognitive impairment and poor 
premorbid functioning (Lindenmayer, 2000; Meltzer, 1997), as well as NSS 
(Smith et al., 1999) have been associated with treatment resistance.  Finally, 
Sheitman and Lieberman (1998) suggested that the accumulation of a critical 
number of neurodevelopmental factors, rather than individual ones, may 

















1.8 Aims and hypotheses 
Evidence to date raises the possibility that TRS may constitute a 
neurobiologically distinct subtype of illness, which is not marked by dopamine 
alterations. While there is sufficient evidence to suggest that the neurobiology of 
most schizophrenia, in general, involves increased presynaptic striatal 
dopaminergic elevation, little is known about whether this abnormality is present 
in patients resistant to antipsychotic treatment.  The lack of this knowledge 
considerably limits the development of much needed novel and more rational 
treatments for this group. 
 
The first study in my thesis has been specifically designed to address this 
important question using high resolution PET scan imaging to investigate DA 
synthesis in a cohort of treatment resistant patients.  I tested the hypothesis that 
the neurobiological difference between treatment resistant patients and 
responders is determined by differences in presynaptic dopamine function.  
Either: a) no alterations in presynaptic striatal dopaminergic function will be 
observed in treatment resistant patients or b) they will have an exceptionally 
hyperactive dopaminergic system that current antipsychotic treatments are 
unable to block.   
 
The second question relates to the issue of whether treatment resistance 
manifests at the outset of illness, for example due to disruption in 
neurodevelopment, or it evolves over time as a result of either a 
neurodegenerative process or neurochemical sensitization.  This was tested in 




hypothesis that TRS tends to manifest at the outset and thus is related to a 
distinct subtype rather than a stage of illness.   
 
Finally, using the same cohort, it was possible to investigate whether and which 
neurodevelopmental factors may predict treatment resistance, and thus test 




Chapter 2  Methodology 
In this chapter the core methodological principles and issues pertinent to both 
treatment resistance and PET studies are described.  First, the important issue 
of defining treatment resistance and remission in schizophrenia is considered.  
This is followed by a description of general principles underlying PET scanning 
and basic procedures of PET image analysis. The details of recruitment, sample 
characteristics, methodology and analyses performed in each study will be 
described in subsequent separate chapters. 
 
2.1 Defining treatment response in schizophrenia 
2.1.1 Defining ‘treatment resistance’ 
 
The definition of treatment resistance in schizophrenia is an intricate process.  It 
is generally accepted that TRS refers to a continuous course associated with 
substantial impairment in functioning, in which symptoms persist despite 
standard psychopharmacological treatment.  However, the literature has been 
historically limited by inconsistencies in defining ‘treatment resistance,’ which 
could be attributed to difficulties related to disentangling illness severity from 
chronicity, or illness progression (Caspi et al., 2004). 
 
In the absence of a universally accepted definition, studies have opted for 
different operational criteria, largely dependent on study aims and population 
used, which has resulted in disparity in response rates. Thus, studies recruiting 
patients for novel antipsychotic drug trials may use more stringent criteria than 




is clear, however, that any definition of treatment resistance should indicate that 
the patient has received an adequate trial of antipsychotic medication in terms 
of both dosage and duration.  It is therefore essential to carefully assess for 
non-compliance or inadequate dose given prior to categorising a patient as 
unresponsive to medication.   
 
Among the most renowned criteria for defining treatment resistance are those 
delineated by Kane and his collaborators for the Multicenter Clozapine Trial 
(Kane et al.,1988).  Kane and colleagues were first to demonstrate clozapine 
effectiveness in schizophrenia patients who failed to respond to conventional 
antipsychotics.   
According to these, prior to patients being deemed to be treatment resistant 
they are required to have: 
 
1. A trial of at least three conventional antipsychotics from two different 
chemical classes at doses of ≥1000 mg chlorpromazine equivalents per 
day, lasting at least 6 weeks each. 
2. No period of good functioning in the last five years. 
3. Persistent moderate or severe psychopathology according to the Brief 
Psychiatric Rating Scale and Clinical Global Impressions criteria.   
 
These criteria are considered highly stringent and permit the inclusion of the 
most severely ill schizophrenia patients only, who in addition, failed a 
prospective trial of haloperidol at doses of at least 60mg per day.  However, in 
clinical setting patients show a varying degree of treatment response and 




those who are refractory to treatment. Evidently, there is a proportion of patients 
who fail to meet such treatment-resistance criteria, but still display moderate to 
severe negative or affective symptoms associated with poor social functioning.  
Thus, it may be more beneficial both in the research and clinical setting to 
assess treatment response as a continuum rather than use the strict criteria that 
categorize patients in one or the other subgroup (Meltzer 1997).  
 
Due to the stringency of Kane’s criteria, all of the three aspects of the first 
criterion specifically, the number of medication trials, the dosage and the 
duration, have been modified since.   It has been demonstrated that patients 
who do not respond to two medication trials have less than a 7% chance of 
responding to a third antipsychotic (Kinon et al., 1993). It is now generally 
accepted that two prospective drug trials are sufficient when defining treatment 
resistance (Barnes and McEvedy, 1996; Conley and Buchanan, 1997). 
Similarly, following important findings that chlorpromazine doses ≦ 400 mg per 
day block 80 to 90% of dopamine receptors (Farde et al.,1994) and that higher 
doses, even in those who are considered resistant, are unlikely to produce 
direct therapeutic benefit (Wolkin et al.,1989), chlorpromazine equivalent of 
400–600 mg antipsychotics is a current standard dose for an adequate 
treatment trial.  Thus, treatment resistance began to be defined as treatment 
failure to at least two different classes of antipsychotics administered for longer 
than 4 weeks in appropriate doses.  Thus, for instance, Bondolfi and colleagues 
in their risperidone versus clozapine trial defined resistance as treatment failure 
to at least two different classes of antipsychotics administered for longer than 4 




“appropriate dose” (Bondolfi et al., 1998), nor do they specify what proportion of 
their treatment resistant patients are treatment-intolerant. Furthermore, 
according to the UK National Institute for Clinical Excellence (NICE) criteria, a 
patient is considered treatment resistant if there is no satisfactory clinical 
improvement despite the consecutive use of two antipsychotics, one of which 
should be an atypical at recommended doses for 6 to 8 weeks duration (NICE, 
2002).  Finally, a 4- to 6-week duration of antipsychotic trial is now considered 
adequate (reviewed in Conley and Kelly 2001).  However, Agid and colleagues 
have shown that whilst a great majority of FEP patients respond to initial 
antipsychotic treatment, a considerably lower response rate of less than 20 
percent was observed with a second antipsychotic trial.  Thus it has been 
advocated that clozapine should be considered early in the treatment of FEP 
patients, who do not respond to other second-generation antipsychotics within 
the first month of treatment (Agid et al., 2007; Agid et al., 2011).   
 
Considering all the factors described above, in particular that the original Kane 
criteria are too stringent, the modified Kane’s criteria have been used in the 
present work (Chapters 3 and 4) to identify treatment resistant patients. 
According to these, treatment resistance is identified if, despite a trial of at least 
two sequential antipsychotic for the 4-6 week duration, and at a dose of 400–
600mg chlorpromazine equivalents/day, patients continued to experience 
persistent psychotic symptoms of at least moderate severity on one or more 
items on the positive symptom sub-scale of the PANSS (Kay et al., 1987), a 
total PANSS score of 75 and above (Leucht and Kane, 2006) and poor global 




(GAF), corresponding to at least moderate functional impairment as indicated in 
Chapter 3. 
 
2.1.2 Defining symptomatic remission in schizophrenia 
 
Similarly to defining treatment resistance, deciding what constitutes 
symptomatic treatment remission in schizophrenia has not been an easy 
process. First, for remission criteria to be applied patients have to have a 
diagnosis reached using recognized criteria; the second consideration relates to 
fact that remission does not equate to recovery, and finally patients can achieve 
remission spontaneously, that is without psychopharmacological treatment (Van 
Os et al., 2006). The issue of standardizing treatment remission has been 
considered by two working groups in recent years (Andreasen et al., 2005; Van 
Os et al., 2006).  The US working group led by Andreasen, reached a 
consensus definition on remission in schizophrenia, and subsequently 
developed specific standardized operational criteria for its assessment.  These 
criteria take into consideration two factors (for details see Chapter 3): 
 Low symptomatic scores on the Positive and Negative Syndrome Scale 
(PANSS), but the symptom severity can also be determined by using the 
BPRS.  








2.2 General principles of PET imaging and analysis   
 
PET is based on radioactive positron emission that was first discovered in 1933 
(Joiot F, 1933; Thibaud J, 1933) following Anderson’s discovery of the positrons 
in cosmic radiation (Anderson, 1932). It provides a unique and exciting 
opportunity for quantifying specific neurotransmitter alterations in a living human 
brain, at a very high sensitivity, which is unparalleled by other brain imaging 
modalities.  Over the last 20 years, it has been extensively applied in psychiatric 
research, and permitted the investigation of the pathophysiology of 
schizophrenia and mechanisms of actions of antipsychotic drugs, providing 
important findings in both domains with significant subsequent theoretical and 
clinical implications. PET scanning requires administration of a short-lived 
positron emitting radiotracer (the radioisotope) into the blood circulation and 
subsequent tomographic imaging of the radiotracer distribution.  
 
2.2.1 Radiochemistry and properties of radiotracer [18F]-DOPA  
 
Production of radiotracers is a highly specialized, time consuming and 
expensive procedure that has to be approved by national and international 
regulatory agencies.  Radiotracers used in brain imaging must be able to cross 
the blood-brain barrier, have limited plasma and non-specific binding, peripheral 
metabolism and have appropriate kinetics for the study duration. Strict quality 
and pharmaceutical control requires tracers to be free of contamination by other 
radionuclides and toxic organic solvents and must guarantee sterility, stability, 
apyrogenicity and optimal pH and osmolality.  The radiotracers are unstable 




scanning centre and used virtually immediately after their synthesis.  Therefore 
an onsite cyclotron, which is a compact subatomic particle accelerator, is useful, 
and often necessary, for short-half live radiotracers (Miller et al., 2008).  The 
PET facility centre at the Hammersmith Hospital where the present work was 
conducted has an on-site cyclotron and radiosynthetic laboratory, in close 
proximity with PET scanners that permitted efficient manufacturing and 
transport of [18F]-DOPA to the scanning room. The cyclotron, using powerful 
magnetic and electric fields that are positioned at a right angle within a vacuum 
chamber, energizes a beam of charged particles that then bombards stable 
target elements to induce a series of nuclear reactions, which gives rise to 
unstable positron emitting isotopes.  In the following stage, the isotope is 
incorporated into the organic compound of interest.  This process does not 
significantly affect the biochemical properties of the original compound (Miller et 
al., 2008). 
 
One of the most widely used radiotracers for imaging the dopaminergic system 
is [18F]-DOPA that was first applied for clinical use in 1983 (Garnett et al., 
1983). The positron emitter, 18F used here to label DOPA, is produced by 
bombarding 18O with protons, which results in the nucleus losing a neutron and 
gaining a proton.  It has a relatively long half-life of 110 minutes, which is 
considerably longer than that of many other radioisotopes and hence does not 
always necessitate on site production. Once injected, [18F]-DOPA is transported 
across the Blood Brain Barrier (BBB), then decarboxylated to [18F] - Dopamine 
by AAAD, and stored in DA vesicles.  Similar to DA, it is further metabolized by 




metabolites exit the brain in a slow manner, therefore during the measurements, 
the activity usually accumulates during the measurement times that typically last 
up to 90 minutes (Cumming et al., 2001).  In healthy subjects, F-DOPA images 
taken for 90 minutes following the peripheral injection of this radiotracer show 
high affinity for the brain areas richest in AAAD such as the striatum (caudate 
and putamen) and the mesencephalon, but significantly lower for the cerebral 
cortex or cerebellum (Herholz K et al., 2004). 
 
2.2.2 Exposure to Radiation 
 
There are associated risks of radiation exposure, in terms of DNA cellular 
damage, to both participants and the personnel involved in PET scanning 
procedures. The use of radiotracers, therefore, is rigorously regulated by 
ARSAC (UK) whose permission is required prior to the commencement of 
molecular imaging studies.  The effective dose of 5-10 mSv is considered to be 
safe and in the range within which the risk is so small that it could be 
administered safely even in healthy volunteers.   
 
2.2.3 PET data acquisition 
 
Whilst undergoing decay, radiotracers emit positrons, the antiparticles of 
electrons, from radioactive nuclei, that travel a short distance of approximately 
1-3 mm through a tissue, and when decelerated collide with surrounding slow 
moving electrons generating simultaneously a pair of annihilation gamma rays 
(or photons). The paired gamma rays are then detected as a ‘coincident event’ 
by PET scanners (or cameras) via scintillation crystal detectors, configured as 




other, which makes the identification of the source of origin fairly accurate, i.e. 
they are likely to have occurred from a single annihilation event, somewhere at 
the point along the straight line between the two detectors.  These lines are 
known also as a “lines of coincidence” or “lines of response” (LOR).  The 
annihilation event will be recorded only if both detectors are activated 
simultaneously.  During scanning time millions of coincidence events are 
registered forming a great number of LORs that are recorded and saved by PET 
scan computers as 2 dimensional matrices known as sinograms.   During this 
process a few of the photons are absorbed by the surrounding tissue through 
which they first need to pass in order to reach the detectors, a process referred 
to as ‘attenuation’.  This results in a loss of detection of true coincidence events, 
which in turn leads to increases in noise, image artefacts, and image distortion. 
Therefore, prior to reconstruction of three-dimensional images, the sinogram 
data must be first corrected for attenuation (a process known as attenuation 
correction) and in addition for scatter, which occurs when photons are deflected 
by a collision with an electron, thus changing direction.  Scatter correction is 
one of the most complex correction procedures. The three-dimensional images 
of corrected sinograms in the brain are reconstructed by specific computer 
analysis using filtered back-projection algorithms. Thus the PET image 
quantitatively reflects the dynamic radiotracer distribution in the specific region 
of brain over time.  These reconstructed images are then formatted as a series 







Figure 2.1 Simplified diagram of PET data acquisition. (Partly adapted 




Radiotracers emit positrons from radioactive nuclei, that travel a short distance through 
a tissue, and when decelerated collide with surrounding electrons generating 
simultaneously a pair of annihilation gamma rays, which are then detected as a 
‘coincident event’ by PET scanners. The three-dimensional images of corrected 
sonograms (2 dimensional matrices) in the brain are reconstructed by specific 
computer analysis using filtered back-projection algorithms.  These images are then 
formatted as a series acquired during adjacent time periods, which are known as 






2.3 General principles of PET image analysis 
2.3.1 Head movement detection and correction  
 
Head movements, that may be expected even in the most co-operative 
subjects, during longer acquisition times can be a source of artefacts and image 
degradation, and as such present one of the major caveats in PET, but also 
other techniques of brain imaging.  Significant head movements can potentially 
distort the data by either decreasing or increasing the signal, which is 
dependent on radiotracer concentration in tissues that surround regions of 
interest.   
 
Numerous physical methods have been used in an attempt to minimize head 
movement. For example head restraints, such as individually moulded 
thermoplastic masks clamped to the scanner table, were used in two healthy 
volunteer studies (Green et al.,1994; Ruttimann et al.,1995).  Although it was 
demonstrated that the effects can be reduced significantly by using these 
masks they fail to reduce head movement fully, and some, particularly patients 
with complex psychiatric or neurological disorders, could find these restraints 
uncomfortable to a degree that this would potentially result in increased 
movement.  
 
An alternative strategy is to use an optical tracking system which enables head 
position measurements during the scan and subsequent movement correction 
conducted prior to image reconstruction (Goldstein et al.,1997; Montgomery et 





The effects of head movement on image quality during data acquisition can be 
corrected for and therefore be minimized by performing post-hoc frame-by 
frame (FBF) realignment of the data (Mawlawi et al., 2001).  This is performed 
by realigning frames either to an initial frame or to a frame chosen for its high 
signal to noise ratio. In this thesis, the FBF realignment to a single frame 
acquired 7 minutes after [18F]-DOPA injection was employed (Chapter 3).  This 
method may have several potential limitations: it can give rise to artefacts 
between frame movements due to differences in radiotracer distribution 
between early and late frames, fails to correct for movement that occurs within 
frames, and finally it may lead to an incorrect attenuation correction as it is 
unable to account for movement that occurs between the transmission and 
emission scans.  
 
Nevertheless, Montgomery and colleagues directly compared FBF realignment 
with a motion tracking system using a series of 11C-raclopride scans to 
examine their effect on both test-retest reliability (potential differences at 2 time 
points may be attributable to head movement), and noise in the data. They 
found that both methods of realignment were superior to the raw data, and 
although motion-tracking system performed better than FBF in some indices, 
FBF still dramatically improved the accuracy of data.  For example, using FBF 
realignment of PET data, the variability of the ventral striatal signal was reduced 
from 13.5 percent, observed with row data, to 7.3 percent.   Once realigned the 
time frames are integrated in a single summation dynamic image, known also 




2.3.2 General methodology of spatial normalization 
 
Prior to entering statistical analyses, the dynamic images need to be normalized 
to a template first, which is essential when analysing data across different 
individuals.  Normalization involves manipulation of individual brain images to 
match an atlas template.  In other words, it registers images from different 
participants into approximately the same co-ordinate system which is achieved 
by using coregistration algorithms. The presence of considerable inter-individual 
anatomical variability in respect to a standard co-ordinate system necessitates 
atlases to be based on multiple subjects.   
 
One of the most popular co-ordinate systems was developed by Talairach and 
Tournoux (Talairach J and Tournoux P, 1988), however, it is based on the 
transaxial planes that are demarcated by white matter structures, therefore not 
suitable for PET images where white matter is not visible.  A standard brain 
atlas that is close to the Talariach coordinate system was created from 305 
normal subjects at the Montreal Neurological Institute (MNI) (Evans et al., 
2006).  It is internationally recognized as the MNI standard brain atlas template 
for spatially normalized brain PET scans. For each tracer separate templates 
are created.  For instance, the [18F]-DOPA template used in the present study 
was created by several groups at Hammersmith Hospital from previously 
acquired images, using the same imaging protocol.  
 
The described method was used for voxel based analysis where the parametric 
image for each patient was normalized into standard space, using the patients’ 




used, however, in ROI analysis differs somewhat; here, the [18F]-DOPA atlas 
template was normalized together with ROI map (see the following section) 
individually to each subject’s dynamic summation PET image, which remained 
in native space.  Using this method, observer bias that can occur when defining 
ROIs for each subject, is avoided.  Moreover, this way the sampling volume is 
adjusted to the individual’s striatal volume, mitigating to some extent against 
partial volume effects that may otherwise introduce biases in radiotracer uptake 
measurements (Chapter 3).  
  
2.3.3 Regions - of - interest (ROI) approach  
 
The striatum is rich in AAADC, and as such is a region of particular interest for 
measurements of [18F]-DOPA uptake.  As described in a previous chapter, the 
striatum can be topographically organized into functional subdivisions along the 
dorsolateral to ventromedial gradient. In earlier dopaminergic studies 
investigation of dopaminergic transmission was only possible for the striatum as 
a whole, which precluded more precise identification of dopamine abnormality in 
schizophrenia (Martinez et al., 2003).  However rapid and powerful advances in 
PET imaging resolution permit [18F]-DOPA uptake measurements even on this 
sub-divisional level. This is highly important, as recent literature has 
demonstrated that certain striatal structures may be associated more strongly 
with schizophrenia.  From recent studies it appears that associative striatal 
subdivision is more important than other functional subdivisions for 
schizophrenic pathophysiology (Kegeles , 2010).  Congruently, Nozaki and co-




increased in the caudate nucleus that anatomically corresponds to the 
associative subdivision.  
 
In this present work, the regions of interest map that were defined in MNI space, 
comprised the whole striatum and its functional subdivisions, and in addition the 
cerebellum that acted as a reference region.  As described in the previous 
section, the ROI map was normalized together with the [18F]-DOPA atlas 
template to each individual PET scan. Correspondingly [18 F]-DOPA influx rate 
constants (Ki values) were calculated, using graphical analysis (Patlak et al., 
1983), in the whole striatum and its sensorimotor (SMST) associative (AST) and 
limbic (LST) functional subdivisions relative to uptake in reference region (see 
Chapter 3). 
  
2.3.4 Statistical parametric mapping (SPM) 
 
A voxel-based comparison using SPM permits identification of significant 
differences at a voxel level across scan datasets that allows both between‐
group and within‐group analyses. Using this approach, all the individual 
parametric images are first smoothed to improve the signal to noise ratio and 
compensates for slight inter-individual anatomical differences, and then 
normalized into the same three-dimensional standardized space using an 
isotropic Gaussian kernel.  This way, each voxel from the data set in question is 
in the same stereotactic location as a corresponding voxel from a comparison 
data set, so that subsequent analyses can be performed at a voxel level using 
the general linear model (Friston et al., 1995).   For each contrast a t statistics is 
computed for each voxel to produce a SPM (t).  The SPM (t) is subsequently 




degrees of freedom. Following this, voxel based Z scores are collected into a 
3D image, which is termed as statistical parametric map or Z map.  The SPM 
constitutes a large number of measures over the brain. Significant clusters of 
mean group differences can then be identified, using appropriate thresholding 
that accounts for the large number of comparisons.  These are then projected 
onto a 3D glass brain or a single subject T1 MRI image (Figure 2.2). 
 
Figure 2.2 Between-group comparison using SPM 
 
 
Statistical comparisons across scan datasets in corresponding voxel regions of the 
brain. Voxels with significant differences in mean tracer uptake are automatically 
transferred onto a standard T1 MRI. 
 
2.3.5 Comparison between ROI and SPM methods 
 
The ROI approach allows for the sampling of a tracer uptake in specific and 
preselected areas of the brain, identified as regions of interest, to address the 
specific research questions, based on an a priori hypothesis. It examines 
activity within a set of voxels that are functionally related. In this work, as 
previously described, the preselected regions of interest comprised the whole 




striatum may not always be detected by a traditional ROI analysis.  Statistical 
parametric mapping, on the other hand permits localisation of statistically 
significant changes on a voxel by voxel basis, without previous assumption of 
the distribution of differences between the images. It has been shown that SPM 
can be successfully applied to [18F]-DOPA PET images (Ito et al.,1999).  
Furthermore, application of SPM permits examination of dopaminergic function 
in other brain regions outside the striatum, which could not be determined with 
the ROI approach.  Therefore, both methods of image analysis, the automated 
ROI approach and SPM were used in the first thesis study (Chapter 3) to 






















As discussed earlier, a significant proportion, perhaps up to one third, of 
patients with schizophrenia show only a limited response to antipsychotic 
treatment (Lindenmayer et al., 2005). This ‘treatment resistance’ is a major 
clinical problem, impairing the lives of these patients.  Over the last two 
decades, radiolabelled DOPA PET studies have directly demonstrated that 
elevated presynaptic striatal dopaminergic function is a robust feature of 
schizophrenic pathophysiology (Chapter 1). However, the relationship between 
this abnormality and the response to antipsychotic treatment remains unclear. 
 
There is substantial evidence to suggest that the efficacy of antipsychotic drugs 
is related to dopamine D2 receptor blockade (Kapur et al., 2000).  All currently 
licensed antipsychotic medications block dopamine receptors (Talbot et al., 
2002), and their relative clinical potency closely parallels their affinity to bind 
and block the dopamine D2 receptor subtype (Creese et al.,1976).  PET studies 
have indicated that at least 50% occupancy of D2 receptors is necessary to 
achieve clinical response (Abi-Dargham et al., 2005).  Both PET and SPECT 
studies that have investigated D2 receptor occupancy specifically in treatment 
resistance in schizophrenia found almost identical levels of striatal dopamine 
receptor occupancy in responders and non-responders, suggesting that whilst 
adequate D2 blockade may be necessary for a therapeutic response, it does 




et al., 1992).  The limited data available suggests that patients who do not 
respond to current dopamine-blocking treatments may have a lower level of [18 
F]-DOPA uptake than those who respond to dopaminergic blockers (Abi-
Dargham et al., 2005; Duncan et al., 1993).  However, it could also be argued 
that patients who do not respond have an exceptionally hyperactive 
dopaminergic system, which is not blocked by current antipsychotic treatments.  
This study was specifically designed to address this issue by using [18F]-DOPA 
PET to compare dopamine synthesis capacity in patients that had either shown 





Two groups of patients were recruited, defined according to their response to 
antipsychotic treatment; all met DSM IV criteria for Schizophrenia, paranoid 
subtype determined by using Operational Criteria Checklist (OPCRIT) (McGuffin 
et al., 1991).  The Treatment Resistant group (n=14) comprised patients who 
met modified Kane criteria for treatment resistance (see Chapter 2.1).  
According to these, all of these patients had received at least 2 prior sequential 
antipsychotic trials each of at least 4-6 weeks in duration at a dose of 400–
600mg chlorpromazine equivalents/day, but had continued to have persistent 
psychotic symptoms defined as a rating of at least moderate severity on one or 
more items on the positive symptom sub-scale of the PANSS (Kay et al., 1987), 
a total PANSS score of 75 and above (Leucht and Kane, 2006) and poor global 




(GAF), corresponding to at least moderate functional impairment.  The 
Responder group (n=12) comprised patients who met the Remission in 
Schizophrenia Working Group Criteria for treatment remission (Andreasen et 
al., 2005).  These patients scored 3 or less on all items of the PANSS 
(corresponding to mild severity or no symptoms), and had not experienced a 
symptomatic relapse in the 6 months prior to the study.   
 
All patients were recruited from the South London and Maudsley NHS Trust.  A 
group of healthy controls (n=12), with no previous or current history of 
psychiatric illness as assessed by the Structured Clinical Interview for DSM-IV 
Axis I Disorders (SCID-I) and the Structured Clinical Interview for DSM-IV 
Personality (SCID-II), and no family history of psychosis, were recruited through 
advertisement in the press.  The groups were matched for age, sex, ethnicity, 
weight, and for smoking.  Treatment Resistant patients and Responders were 
matched, in addition, for duration of illness and for antipsychotic dosage 
expressed in chlorpromazine equivalents. All antipsychotic doses were 
converted to chlorpromazine equivalents, according to the published 
equivalencies (Ho et al., 2011; Woods 2003; Taylor et al., 2012)  
 
All patients were receiving antipsychotic medication other than clozapine at the 
time of scanning.  Two patients (from the Treatment Resistant group) had been 
previously treated with clozapine, but it had been discontinued due to side 
effects, without reaching therapeutic blood levels.  Compliance to medication 




reviewing pharmacy and medical records.  Subjects were excluded if, prior to 
the scan, there was evidence of non-compliance at any point in the six months 
prior to scanning, or where serum levels were not at adequate levels.  Exclusion 
criteria for all groups were pregnancy (all women received a pregnancy test 
prior to scanning), contraindication to imaging, history of neurological or active 
medical illness or head injury, or alcohol or other drug abuse or dependency.  
All subjects received a urine drug screen prior to scanning and were excluded if 
this was positive for illicit substances. 
 
One patient was excluded from the Treatment Resistant group because he did 
not complete the scanning, and another Treatment Resistant patient withdrew 
from the study.  The data analysis was therefore restricted to 12 Treatment 
Resistant patients, along with 12 Responders and 12 healthy volunteers.   
 
The protocol was approved by the Institute of Psychiatry, King's College London 
research ethics committee, and permission to administer radioactive 
substances was granted from the Administration of Radioactive Substances 
Advisory Committee, United Kingdom.  All subjects, following a full description 
of the study, gave written informed consent to participate. 
 
3.2.2 PET Protocol 
 
The participants were instructed to fast and to refrain from caffeine, tobacco, 
and alcohol, for at least 12 hours before scanning. One hour prior to the start of 
each scan, all subjects received 150 mg of carbidopa, a peripheral AAADC 




inhibitor orally, to increase specific signal detection, as these compounds 
reduce the formation of radioactively labeled metabolites that may cross the 
blood-brain barrier and thus confound the measurements.  
3.2.3 Data acquisition 
 
PET imaging data were acquired on an ECAT EXACT HR+ 962 PET scanner in  
3D mode, with an axial field of view of 15.5cm, which provides 63 transaxial 
planes. This camera has an axial resolution of 5.4 mm full width at half 
maximum (FWHM) and a transaxial resolution of 5.6 mm FWHM at 10 cm 
distance from the centre (Brix et al., 1997).  Subjects were positioned in the 
scanner with the orbitomeatal line parallel to the transaxial plane of the 
tomograph.  Head position was monitored via laser crosshairs, video camera 
and direct observation throughout the scanning period. To correct for 
attenuation, an initial 10-minute transmission scan was conducted prior to 
radiotracer administration. Approximately 180 MBq of the [18F]-DOPA was 
injected as a bolus over 30 seconds into the antecubital vein, via a 22g cannula 
and three-way tap, simultaneously with the initiation of a 90-minute dynamic 
PET scan.  Emission data were obtained as 26 frames of increasing duration 
over 90 minutes in list mode, starting with a background frame of 30 seconds, 
followed by injection of [18F]-DOPA at the beginning of four 60-second frames, 
three 120-second frames, three 180-second frames, and, finally, fifteen 300-




Figure 3.1 PET protocol used in experiment  
 
 
Subjects, in addition, underwent structural magnetic resonance imaging to 
exclude intracranial abnormalities.  No gross abnormalities were detected in any 
subject following review by a neuroradiologist blind to the subject group.   
3.2.4 Image analysis  
 
Both automated ROI and voxel-based statistical image analyses, with the 
cerebellum as a reference region, were performed to examine striatal [18F]-
DOPA uptake.  The ROI analysis included the whole striatum and its 
associative, limbic and sensorimotor sub-regions delineated as described in 
Chapter 2.    
 
To correct for head movement, denoising of the non-attenuated dynamic image 
and frame-to-frame realignment to a single ‘reference’ frame acquired 7 minutes 
after [18F]-DOPA injection, was conducted. Then, the transformation parameters 
were applied to the corresponding attenuation-corrected frames, and the 


















image ready for the analyses.  The ROI map was then normalized together with 
an [18F]-DOPA template to each individual PET summation image using SPM5 
(www.fil.ion.ucl.ac.uk/spm), which allows ROIs to be placed automatically and 
without observer bias, on individual [18F]-DOPA PET dynamic images (Figure 
3.2).  
 
Figure 3.2 Striatal ROI map normalized together with an atlas template on 














Green area represents LST, pink area AST, and purple area SMST 
 
Patlak graphical analysis was used to compute striatal [18F]-DOPA influx rate 
constants (Kicer values) to index striatal DA synthesis capacity relative to uptake 




cerebellum is often used in [18F]-DOPA PET studies as a reference region as it 
is known to have the lowest AAADC activity and consequently the lowest DA 
concentration (Brown et al., 1979; Moore et al., 2003).   
 
3.2.5 SPM analysis 
 
Voxel-based statistical image analysis was performed to independently confirm 
the results derived from ROI analysis and determine if there were sub-regional 
differences.  Parametric maps of the influx rate constants for [18 F]-DOPA were 
constructed from movement-corrected images by using a wavelet-based kinetic 
modelling approach that increases the signal-to-noise ratio without affecting 
significantly resolution (see Howes et al., 2009). Following the normalization of 
parametric images, statistical analyses were performed using SPM5, restricted 
to the striatum using a mask, to examine differences between groups.  The 
results presented were analysed corrected for multiple comparisons (p<0.05, 
corrected at the Family Wise Error rate) and, in a further sensitivity analysis, 
without correction. 
 
3.2.6 Statistical analysis 
 
Preliminary tests were conducted to explore the homogeneity of variance, 
regression slopes, normality and reliable measurements of covariate. The 
Kolmogorov-Smirnov test confirmed that the data showed a normal distribution.  
To determine whether there was an effect of group on striatal Kicer values, and 
demographic, striatal volume, and clinical data, analysis of variance (ANOVA) 




in Kicer values between the groups (Treatment Resistant, Responders and 
Healthy Volunteers), following a significant main effect, the posthoc pairwise 
comparisons based on t statistics between each groups were performed.  To 
reduce the risk of a type I error due to multiple testing a Bonferroni correction of 
the p-value was applied.  
 
To assess whether the effect was influenced by medication, an additional 
analysis of covariance (ANCOVA) with medication dose expressed as 
chlorpromazine equivalents added as co-variate, was performed. The 
independent variable was group whereas dependent variables comprised Kicer 
values for striatum and its three subdivisions.  A two-tailed significance 
threshold of 0.05 was used throughout.  In addition, Pearsons’s correlations 
were performed to assess the relationship between the DA synthesis capacity 
and the total PANSS score or the negative and the positive subscales of the 




Sociodemographic and clinical characteristics are presented in Table 3.1. No 
between group differences were observed for age, gender, ethnicity, weight, 
radiation dose received, cigarette smoking, duration of illness, or medication 
dose.  In addition, there were no differences across the groups for the whole 
striatal volume or any of its subdivisions.  The mean ages of treatment resistant 
patients, responders and volunteers were 45.7 [SD=9.8]; 44.0 [SD=11.9] and 




groups comprised 5 males and 7 females each, whereas in a responder group 
there were 6males and 6 females.  The number of smokers was equal in the 
treatment resistant and healthy volunteer groups (n=3), whilst there were 4 
responders that reported smoking.  As it is expected, treatment resistant 
patients received higher medication dose, by 110 mg/day approximately in 
chlorpromazine equivalents, then responders, and had significantly higher total 
PANSS score than responders. Types of antipsychotics that patients were 
receiving at the time of the scanning are presented in Table 3.2. 
 
Figure 3.3 shows the mean dopamine synthesis capacity for the three groups.  
The analysis of variance, identified a statistically significant effect of group on 
Kicer values for the whole striatum (F2,33=5.4, p=0.01), and for each of its 
associative (F2,33=6.7,p=0.004),  limbic (F2,33=4.0, p=0.03) and sensorimotor 
subdivisions (F2,33=3.4, p=0.05).  For mean Kicer values and standard deviations, 
see Table 3.3. 
 
Because one of the patients in the Responder group had particularly high Kicer 
values, we repeated the analysis after excluding this subject.  The group effect 
remained significant for the whole striatum (F2,32=4.2, p=0.02) and its 
associative subdivision (F2,32=6.4, p=0.005 ), but not the other striatal sub-
divisions.  Individual Kicer values are presented on scatter plots before and after 
excluding the subject in question (Figures 3.4 and 3.5). 
 
To assess the effect of antipsychotic medication, the analysis was repeated with 




scanning as a covariate.  The effects of group on Kicer values from the whole 
striatum (F1,22=7.2, P =0.01) and the associative (F1,22=10.2, P =0.005) and 
limbic (F1,22=6.4, P =0.02) subdivisions remained significant, but there was no 
longer a significant difference in the sensorimotor subdivision.   
 
Regarding the correlations between DA synthesis capacity and the symptom 
scores, in TRS there were no significant associations between the whole striatal 
Kicer values and the total PANSS, or its positive or negative subscale scores 
(r=0.11, r=-0.07, r=0.52 respectively).  Whilst in Responder group, the 
significant relationship between DA synthesis capacity was observed between 
DA synthesis capacity and total PANSS and the negative subscale sores 
(r=0.60, p=0.039; r=-0.67, p=0.016 respectively), these associations no longer 
remained significant after removal of the subject with exceptionally high Kicer 
values (r=-0.36, p=0.27; r=-0.59, p=0.06), suggesting that significant 







   
   
   
   
   
    
      
   
   
   
   
   






































   
   
   
   
   
   
   
   






















































































































































   
   
   







   
   
   














































































































































































































































































































































































































aThere are no significant differences between groups 
 
Antipsychotic 
Treatment Resistant Responders 
N % N % 
Olanzapine 3 25.0 2 16.7 
Quetiapine 2 16.7 1 8.3 
Amisulpride 1 8.3 1 8.3 
Risperidone 1 8.3 0 0.0 
Risperidone depot 2 16.7 3 25.0 
Aripiprazole 0 0.0 1 8.3 
Chlorpromazine 1 8.3 0 0.0 
Zuclopenthixol Decanoate 1 8.3 3 25.0 











aThe treatment resistant group showed significantly lower dopamine synthesis 
capacity than the treatment responders (p= 0.02, corrected for multiple 
comparisons). There were no significant differences between treatment 




































































































































































































































































































































The treatment resistant group showed significantly lower dopamine synthesis 
capacity than the treatment responders (p= 0.02).  There were no significant 
differences between treatment resistant patients and healthy volunteers 
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Figure 3.5 Individual Kicer values for the whole striatum in three groups  









This result remained significant, after excluding the subject identified by the asterix in 
Figure 3.4. The treatment resistant group showed significantly lower dopamine 
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3.3.1 Between Group Comparisons 
 
Treatment Resistant versus Responders 
After adjustment for multiple comparisons, Kicer values were significantly greater 
in Responders than Treatment Resistant patients in the whole striatum (p=0.02, 
corrected; ES = 1.11), and the associative (p=0.008, corrected; ES= 1.31) and 
limbic subdivisions (p=0.03, corrected; ES=1.04). There was no significant 
difference in the sensorimotor subdivision (p=0.1, corrected).   
 
Greater Kicer values in Responders than Treatment Resistant patients were also 
observed in the corresponding voxel-based analysis, with a peak in the head of 
caudate (p=0.039), which lies within the associative subdivision of the striatum 
(Figure 3.6).  The difference was significant at p<0.05 corrected for multiple 
comparisons using the family–wise error rate.  The Treatment Resistant 
group>Responder group contrast showed no significant differences, even at an 
uncorrected statistical threshold (p<0.05 uncorrected).   
 
Responders versus healthy volunteers  
Kicer values were significantly elevated in Responders compared to healthy 
volunteers, following multiple comparison adjustments, in the whole striatum 
(p=0.02, corrected; ES= 1.12) and the associative subdivision (p=0.01, 
corrected; ES=1.24), but not in the limbic (p=0.1, corrected), or sensorimotor 
subdivisions (p=0.06, corrected).  Similarly, the voxel-based analysis revealed 
significantly greater Kicer values in the Responder group compared to healthy 
volunteers, with a peak in the caudate (p=0.037, corrected at the family-wise 
error rate).  The voxel-based contrast of the healthy volunteers with Responders 
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showed no significant differences, even at an uncorrected threshold (p<0.05 
uncorrected).   
 
Treatment resistant versus healthy volunteers 
There was no significant difference in mean striatal Kicer values between 
treatment resistant patients and healthy volunteers, in the whole striatum or its 
subdivisions.  This was confirmed with the subsequent voxel based analysis for 
the contrast of the treatment resistant group> healthy volunteer group and for 
the contrast of the healthy volunteer group> treatment resistant group, even at 





















 78  
 
 
Figure 3.6 Increased Striatal Dopamine Synthesis Capacity in Responders 






aThe images show increased dopamine synthesis capacity in Responders 
(N=12), relative to Treatment Resistant patients (N=12). The most significant 
increase was in the head of the caudate nucleus (p=0.039, corrected at the 
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3.4 Discussion 
This study provides direct evidence that dopamine synthesis capacity in 
schizophrenia is lower in patients that are treatment resistant than in those who 
show a good response to antipsychotic drugs.  This suggests that treatments 
that involve the blockade of dopamine receptors may be effective in patients 
that have an elevation of dopamine synthesis capacity, but may be less useful 
in patients in whom dopamine synthesis capacity is relatively normal.   
3.4.1 Limitations 
 
The patients in this study were chronically medicated, which could have 
influenced pre-synaptic dopamine synthesis capacity (Carlsson et al.,1963) 
discussed in some detail in Section 3.4.3.  The two patient groups, however, 
were matched for both the current dose of medication, and the total duration of 
treatment.  The mean daily dose was higher in the Treatment Resistant group 
(reflecting their poor response to treatment), but the difference in dose was not 
statistically significant, and group differences in Kicer values remained significant 
after covarying for medication dose.  Another potential limitation is that patients 
received various types of antipsychotic medication that could have differentially 
affected dopamine synthesis. Again, the groups were relatively well matched in 
terms of generation and type of antipsychotics (presented in Table 3.2).  Two 
patients, one in the treatment resistant and the other in the responder group, 
were on amisulpride. At doses lower than 200mg daily, amisulpride may 
increase dopamine transmission via a preferential blockade of pre-synaptic D2-
like autoreceptors.  However, as these two patients received much higher 
doses, 800 mg and 600 mg daily respectively, than the level for a preferential 
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presynaptic action, and were in different groups, it is unlikely that this has 
affected the results. Only one patient (in the Responder group) received 
aripiprazole, an antipsychotic with the unique properties of being a partial 
dopamine receptor agonist (Miyamoto et al., 2004). Theoretically, partial 
agonists should reduce dopamine synthesis capacity, reflected in a lower Kicer 
value, although in practice little net effect has been observed during chronic 
aripiprazole administration in rats (Der-Ghazarian et al., 2010). As the 
aripiprazole treated individual was in the responder group, a reduction in Kicer 
value would reduce rather than account for the group differences we observed 
between responders and treatment resistant patients. Furthermore, as the Kicer 
values for this individual were similar to the mean Kicer value in this group, it is 
unlikely that including the aripiprazole treated individual has had a major effect 
on the overall results. 
As the group sizes were relatively modest, the possibility that the absence of 
differences in dopamine synthesis capacity between the Treatment Resistant 
patients and controls could reflect limited statistical power should also be 
considered.  However, data from previous studies in schizophrenia suggest that 
the effect size for the elevation in dopamine synthesis capacity measured using 
the same PET protocol is relatively large (>1)4,25 and a formal power calculation 
indicated that a sample size of 12 per group had 80% power to detect an effect 
size of >0.7, using a two group two-sided t-test and p=0.05.  
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3.4.2 Presynaptic dopamine synthesis capacity in TRS 
 
The lack of an elevation in presynaptic striatal dopamine synthesis capacity in 
patients who were treatment resistant could provide an explanation for the 
ineffectiveness of antipsychotic treatment in this subgroup.  This finding is in 
agreement with studies of pHVA in patients prior to treatment with 
antipsychotics: levels were higher in responders than non-responders (Duncan 
et al., 1993). Furthermore, Abi-Dargham and colleagues (2000) found that 
higher synaptic dopamine levels, as indexed by D2 receptor occupancy, were 
associated with a better response to antipsychotic treatment.  There is evidence 
from animal studies that chronic treatment with dopamine blocking 
antipsychotics induces D2 receptor upregulation, which can reduce the efficacy 
of antipsychotic treatment and may lead to breakthrough DA supersensitivity 
(Ginovart et al., 2008; Samaha et al., 2007).  Whether these elevated D2 
receptors may then affect dopamine synthesis in Treatment Resistant patients 
is not entirely clear.  This study was cross-sectional, and therefore cannot 
determine whether presynaptic dopamine synthesis capacity was normal in 
Treatment Resistant patients at the onset of their illness, or whether it was 
initially abnormal, but then some change occurred so that the persistent 
psychotic symptoms were no longer related to a striatal dopamine excess.  
Kolakowska et al., (1985) observed that in most of their treatment resistant 
patients, the response to antipsychotic treatment had been insufficient 
throughout the illness, which led them to conclude that the treatment response 
was linked to the type, rather than stage of schizophrenia.   
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3.4.3 Higher presynaptic dopamine synthesis capacity in 
responders 
 
Significantly higher presynaptic dopamine synthesis capacity was observed in 
patients who showed a good response to antipsychotics, with the strongest 
effect observed in the associative subdivision of the striatum, consistent with 
recent evidence (Howes et al., 2009, Howes et al., 2011, Kegeles et al., 2010).  
While the elevation in the responder group is consistent with some previous 
PET studies in chronic patients (McGowan et al., 2004; Reith et al., 1994), there 
are conflicting reports from other studies in chronic patients with schizophrenia, 
who were not acutely psychotic, at he time of scanning that found no significant 
DA elevation (Shotbolt et al., 2011; Elkashef et al., 2000).   
 
Discrepant results may be due to small samples and hence were underpowered 
to detect the difference or different criteria used in identifying treatment 
response.  The study by Shotbolt and colleagues (2011) had a relatively small 
sample size (n=6) that could have accounted for undetected between group 
differences.  The authors also considered the possibility that, due to this modest 
sample size, they may have recruited an unusual subgroup of patients, which 
this could have limited the interpretation and generalizability of their findings. 
Dao-Castellana and colleagues (1997) observed a non-significant striatal DA 
elevation in patients with schizophrenia and, although Elkashef et al., (2000) 
reported decreased DA function in the ventral striatum, they found the opposite 
in posterior cingulate. Therefore, even in negative studies there is an indication 
of increased presynaptic DA synthesis capacity in schizophrenia (reviewed in 
Howes et al., 1997). 
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One tentative explanation for the paradoxically high dopamine synthesis 
capacity in the face of relative symptomatic remission could be that, in the 
context of chronic exposure to DA D2 receptor blockade, these patients do not 
have enhanced transmission due to the ambient post-synpatic DA D2 blockade.  
However, it is not clear whether antipsychotic drugs do normalise dopamine 
synthesis capacity.  Acute treatment increased dopamine synthesis capacity in 
one study (Vernaleken et al., 2006), although no overall effect was observed in 
another study (Ito et al., 2009). On the other hand, it has been reported that 
longer-term antipsychotic treatment reduces presynaptic dopamine synthesis 
capacity (Grunder et al., 2003), and preclinical studies show that antipsychotics 
induce delayed depolarization block of presynaptic dopamine neurons which is 
more rapid in a rat schizophrenia model that shows increased dopamine neuron 
activity than in wild-type rats (Grace et al., 1997; Valenti et al., 2011).  However, 
the study by Grunder and colleagues (2003) did not include healthy volunteers; 
thus, whilst antipsychotics reduced dopamine synthesis capacity, it remains 
unknown whether antipsychotic treatment normalised dopamine synthesis or 
not.  This study, and some (Howes et al., 2009; McGowan et al., 2004) although 
not all (Elkashef et al., 2000) studies that involved antipsychotic treated 
patients, suggest that dopamine synthesis capacity is not completely normalised 
by antipsychotic treatment. Finally, the effect size seen in the treatment 
responder group approximates that observed in previous studies of dopamine 
synthesis capacity in schizophrenia, including those involving medication 
free/naïve subjects (Howes et al., 2009). Thus, overall, these findings suggest 
that medication does not explain the elevation seen in the responder group.   
 84  
 
 
No associations were observed between symptom scores and Kicer values. The 
lack of the relationship between dopamine synthesis capacity and symptoms 
within treatment resistant group is not surprising. This further indicates that DA 
is not primarily or directly involved, but other neurotransmitters may be 
responsible for psychopathology in this subgroup of patients.  Analogously, 
increased DA synthesis capacity did not correlate with PANSS scores in a 
Responder group.  One explanation could be that these patients were stable 
and remitted for a considerable period of time, as reflected by the relatively low 
PANSS scores, suggesting that correlations may have been underpowered or 
affected by the low variance of symptom severity.  This finding is in line with 
those reported by McGowen et al., (2004) who similarly observed that elevated 
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Chapter 4  Characterization of treatment 
resistance in a longitudinal first episode 
psychosis study: course and predictors  
 
4.1 Background 
There is an on-going debate as to whether TRS is an enduring subtype of 
schizophrenic illness, one that tends to manifest right at the outset, or whether it 
evolves over time as a result of neurodegeneration or neurochemical 
sensitization.  In favour of the first notion is the evidence from a number of 
studies that have linked various underlying neurodevelopmental factors to 
treatment resistance (outlined in Chapter 1). Moreover as suggested by 
Sheitman and Lieberman (1993) these features tend to be most prominent in 
patients that are resistant at the onset, and in addition, they seem to have a 
cumulative effect in generating treatment resistance (Sheitman and Lieberman 
1993).  On the other hand, many authors have postulated that treatment 
resistance evolves, in the context of a long duration of untreated psychosis or 
multiple episodes of illness, and have therefore attributed chronicity to a change 
in responsiveness (Loebel et al., 1992; Wyatt, 1995).  Whilst it is true that the 
majority of patients with schizophrenia show relatively good response in the 
initial phase of illness (Meltzer, 1997), first episode studies have documented 
that up to 20% of patients have persistent symptoms despite treatment, during 
the first episode of illness (Loebel et al., 1992).  An earlier study conducted in 
chronic schizophrenics found that the majority of poor responders were 
unresponsive throughout their illness (Kolakowska et al., 1985). However, the 
studies to date are limited by small numbers, short periods of follow up, and 
imprecise definition of treatment resistance.  The principal aim of the present 
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study was to determine whether treatment resistance manifests at the onset of 
psychosis by examining its course in a large first episode psychosis 
representative sample of patients who underwent a 10-year follow up.  With 
respect to neurodevelopmental predictors of TRS, the literature to date has 
mostly focused on factors related to poor outcome or poor response to 
antipsychotic treatment, which, although related, are not synonymous with 
treatment resistance. Therefore, in this study, the associations of available 
putative neurodevelopmental features identified to be associated with either 
poor outcome, poor response, and in some studies with TRS (Chapter 1; 
Section1), were examined specifically in patients who were resistant at the 
initiation of antipsychotic treatment. Finally, the additive effect of putative 
neurodevelopmental features in predicting treatment resistance was examined. 
Thus, I set out to test the hypothesis that treatment resistance is a 
neurodevelopmentally pre-determined form of schizophrenic illness. 
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4.2 Methods  
4.2.1 Design  
 
AESOP study 
The AESOP study is a 10 year, longitudinal follow-up, population based study 
of all incident cases of psychosis from defined catchment areas (Dazzan et al., 
2008; Fearon et al., 2006).  At a baseline, all patients aged 16–64 years who 
presented with a first episode of psychosis identified in the southeast London 
and Nottingham centres over a 2-year period were approached.  Exclusion 
criteria were: (a) the presence of a disease of the central nervous system; (b) 
moderate or severe learning disabilities as defined by ICD-10; and (c) transient 
psychotic symptoms resulting from acute intoxication as defined by ICD-10.   
At approximately 10 years after inclusion, it was attempted to trace, re-contact 
and re-assess all participants recruited at a baseline and, where possible, they 
were invited to participate in the follow up study.  Ethical approval for both the 
baseline and follow up studies were obtained from the local research ethics 
committees. At baseline recruitment, patients provided detailed contact 
information for themselves, their GPs and relatives, and gave consent to be re-
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4.2.2 Baseline clinical assessment 
Psychopathology was assessed as soon as possible after first contact was 
made with psychiatric services using the SCAN (SCAN; WHO, 1992). Ratings 
on the SCAN were based on clinical interview, case-note review and 
information from informants, when this was available (Fearon et al., 2006). 
Diagnoses were established according to ICD-10 Diagnostic Criteria for 
Research (WHO, 1992) during a series of consensus meetings with senior 
clinicians, including at least one principle investigator, blind to ethnicity, and 
based on all available information for each case, such as clinical vignettes 
prepared by the clinical assessor, and the SCAN interview. There was 80% 
agreement between raters on diagnostic category (kappa values ranged from 
0.63 to 0.75, p<0.001). Further, using factor analysis, baseline symptoms were 
categorized in five psychopathological dimensions: manic, reality distortion, 
negative, depressive and disorganization symptom dimensions (Demjaha et al., 
2009). DUP was defined as the period in weeks from the onset of psychosis to 
first contact with statutory mental health services. The end point for DUP was 
contact with secondary mental health services (for full details, see Morgan et 
al., 2006).  Age of onset was established as the age at which first psychotic 
symptoms appeared.  In line with previous studies (Harrison et al., 1996), mode 
of onset was rated, using the WHO Personal and Psychiatric History Schedule, 
according to two categories: acute (psychotic symptoms appeared 
incrementally within 1 month) and insidious (psychotic symptoms appeared 
incrementally over a period of more than 1 month).  
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Neurological soft signs were assessed as soon as possible after initial 
presentation using an expanded version of the Neurological Evaluation Scale 
(Buchanan and Heinrichs, 1989; Dazzan et al., 2004). 
 
4.2.3 Follow-up clinical assessments 
 
Using an extended version of the WHO Life Chart Schedule (LCS), (WHO 1992, 
1992) extensive information was collected from medical case records, where 
possible, from follow-up interview, and treating clinicians.  LCS includes, in 
addition to items that rate psychopathology and medication use, items that rate 
substance use and details of contact with mental health services. The WHO Life 
Chart, designed to collate information from multiple sources, including medical 
case records, has been successfully implemented in previous long-term follow-
up studies.  Presence of symptoms at follow-up was assessed using the SCAN 
(Version 2). Data from both the WHO Life Chart and SCAN were used to 
determine a lifetime diagnosis in consensus meetings with senior clinical 
investigators and other members of the research team. Data on antipsychotic 
medication prescribing and adherence to medication, throughout the follow-up 
period, were collated from the ward and community prescriptions, 
correspondence from the prescribing clinician, and from the patients’ clinical 
records. Using all available information, case histories were reconstructed over 
the follow-up period to complete all sections of the Life Chart. This involved 
close examination of medication charts, medical records and clinical 
documentation that included reports of drug level testing where available and 
correspondence to general practitioners. Using a Medication History Timeline, 
the start and end date of all prescribed antipsychotic medication, dosage, 
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adherence to treatment; and the reason for change or termination was 
recorded. Data collection was conducted by, or under close supervision, of 
senior clinicians. 
 91  
 
Figure 4.1 Flow chart documenting re-contacting and tracing original 
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4.2.4 Defining treatment resistance and remission 
 
Patients who were receiving clozapine, the only antipsychotic licensed for TRS 
in the UK (Taylor et al., 2007) during the follow up period were defined as 
treatment resistant.  To receive clozapine the patients should meet NICE 
criteria, according to which they should have been treated with at least two 
sequential different antipsychotics (at least one from a second generation 
class), for an adequate duration (minimum 4 weeks), and at adequate dosage, 
with no adequate response to either antipsychotic as demonstrated by the 
presence of psychotic symptoms of at least moderate severity.  The same 
criteria were applied to identify patients who had not yet received clozapine, but 
remained treatment resistant.   
Treatment Response was defined as a state following a psychotic episode, of a 
duration of at least 6 months, in which none of the symptoms or disturbed 
behaviour required to define a psychotic episode were present as listed in a life 
chart schedule: hallucinations or pseudo-hallucinations in any modality, 
delusions, marked thought disorder, marked psychomotor disorder, bizarre or 
inappropriate behaviour, severe excitement or aggression, loss of interest, 
social withdrawal, states of overwhelming fear or severe anxiety, and gross and 
persistent self-neglect. 
  
4.2.4.1 Defining treatment resistance at onset 
 
Patients were classified as treatment resistant from the onset, if from the time of 
first ever initiation of antipsychotic treatment, they continued to exhibit psychotic 
symptoms of at least moderate severity despite receiving medication of 
adequate dosage (at least 400mg chlorpromazine equivalent) for at least 4 
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weeks and, which did not remit when treated sequentially with a different 
antipsychotic in adequate dosage for a minimum duration of 4 weeks.    
4.2.4.2 Defining symptom severity 
 
SCAN rating scale was used to assess the severity of psychotic symptoms.  
The ratings were based on duration, persistence, degree of interference with 
social functioning, effect on other people and frequent contact with services. 
Moderate severity (score 2) corresponds to symptoms being definitely present, 
on multiple occasions or for part of the time at a level sufficient to use in 
classification. Severe psychotic symptoms (score 3) was assigned to symptoms 
that have been continuously present throughout episode and in severe form, 
significantly interfering with functioning. 
   
4.2.5 Statistical analysis 
 
Analyses were performed using the SPSS (version 15.0; SPSS Inc., USA) 
computer software.  To characterize the sample, a descriptive analysis was 
conducted, with the results expressed as frequencies and percentages or 
means ± standard deviations (SDs) as appropriate.  Potential differences 
between the subjects with complete and incomplete clinical information in terms 
of demographic and clinical variables, were examined using Fisher’s Exact or 
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4.2.5.1 Logistic regression 
 
Logistic regression model was performed to calculate adjusted odds ratios 
(ORs) and 95% confidence intervals (CIs), and thus assess the effect of 
available neurodevelopmental factors (see Chapter1; Section 1.6.2) on 
treatment resistance. First, the relationship with individual variables: age of 
onset, gender, NSS and the negative symptom dimension was examined.  The 
model consisted of the independent variables that showed statistically 
significant associations with treatment resistance: age of onset, gender, and the 
negative symptom dimension. Scores on treatment outcome (treatment 
resistance and treatment response) were entered as the dependent (outcome) 
variable.  Second, to test the additive effect of neurodevelopmental factors on 
treatment resistance, a composite neurodevelopmental score was derived, by 
summing the scores on negative dimension (score 1 assigned to the presence 
of negative symptoms), age of onset (score 1 assigned if age of onset was 
below median) and NSS (score 1 assigned to scores above the median NSS 
score). This composite score was then entered as an independent variable and 
treatment response score as the dependent one.  Although information was 
collected for MPA’s, Family History and Premorbid IQ, this was only available 
for a very small number of the analytic sample and hence it was not possible to 
include these in the regression analyses.  
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4.3 Results 
4.3.1 Characteristics of analytic sample    
   
Of the 557 cases that were initially recruited, the follow up assessment was 
completed for 411 cases (see Figure 4.1).  There were no significant differences 
in terms of gender, ethnicity, study centre, DUP or diagnosis between cases 
that the assessment was completed for, and those who were lost to follow up.  
However, the subjects who did not complete the study were significantly older 
than those who did (t=2.5; p=0.02).  The information including medication, 
adherence to treatment and symptom ratings was complete and sufficient for 
270 (48%) patients.  These subjects did not differ from subjects with incomplete 
information (n=287) in terms of age, gender, ethnicity, study centre, DUP or 
diagnosis. Of these, 73 (27%) were identified as Treatment Resistant and 190 
(70%) met criteria for treatment response.  The remaining 7 (3%) couldn’t be 
classified into either category, as they had never received an adequate trial of 
antipsychotic medication. Clinical and demographic characteristics of the 
Treatment Resistant Patients and Responders are presented in Table 4.1.  
About two thirds of treatment resistant patients were male, over 90% had 
diagnosis of schizophrenia, 40% were white British, a third had no 
qualifications, and the median DUP was 24 (interquartile range 4–101) weeks.   
 
Responders had higher, by approximately 5 years, age of onset than treatment 
resistant patients, about half were males, 65% were diagnosed with 
schizophrenia, 43% were white British and the median DUP was 6 (interquartile 
range 2–24) weeks.   
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Table 4.1 Clinical and demographic characteristics of the analytic sample 
 
*The 61 patients that had been Treatment Resistant from the onset are a 
subgroup of the Treatment Resistant group, n=73. Of these, (n=73), 50 patients 












Age of Onset in years 
Mean [SD] 
25.2 [7.7] 30.5 [10.6] 24.7 [6.9] 
Gender 
 
   Male 











   White British 
   Black Caribbean  
   Black African  
   White Other  
   Asian    












  86 [45.3] 
  51 [26.8] 
  24 [12.6] 
13 [6.8] 
11 [5.8] 









Mode of Onset 
 
   Acute 
   Insidious 
















   Schizophrenia 
   Manic 




 2 [2.7] 





 35  [18.5] 








   Any qualification 
   No qualification 





  5 [14.8] 
  






  5 [18.1] 
 











Length of follow-up period 
in years  Mean [SD] 9.3 [2.21] 9.9 [2.05] 9.6 [2.32] 
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4.3.2 The course of treatment resistance 
 
Rigorous examination of the relevant clinical information, using the life chart 
schedule that included information on presence, severity of symptoms, and 
medication data during the follow up period, revealed that a majority of patients, 
61 (83%) of the treatment resistant sample, representing 15% of the follow up 
sample had not responded to antipsychotic treatment right from first 
presentation and initiation of treatment. 
 
 Twelve (17%) patients, who had initially responded to treatment, fulfilling 
criteria for remission outlined in Section 4.2.4, had become resistant to illness 
during the course of their illness. On qualitative exploration, patients who 
developed resistance to antipsychotics later in their illness were predominantly 
males (n=9), had a later age of onset by approximately 3 years than those 
resistant from beginning, 5 were white British, all had diagnosis of 
schizophrenia, and the majority (9) were commenced on clozapine. They 
developed treatment resistance 5 years, on average, after initial presentation 
and treatment, and had about 4 admissions prior to becoming resistant 
(between 1 and 18 each).  Only one patient in this group had a history of 
substance misuse.  
 
For 3 patients who were receiving clozapine there were not sufficient data on 
psychopathology, and therefore it wasn’t possible to determine whether their 
resistance had been present from their first psychotic episode. However, the 
fact that one of these patients had received clozapine within the first year of 
presentation and that the other two were on high doses of antipsychotics right 
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from the initiation of psychopharmacological treatment increases the likelihood 
that these patients too may have been resistant to treatment from the onset. 
 
4.3.3 Predictors of persistent treatment resistance 
   
As presented in Table 4.2, treatment resistance was associated significantly 
with younger age of onset (OR=0.95, 95% CI 0.89-0.97), male gender (OR= 
2.37, 95% CI 1.27-4.46), and higher scores on negative symptom dimension at 
baseline (OR=1.24, 95% CI 1.08-1.43). There were no significant associations 
with NSS. Following adjustment for potential confounders (DUP, diagnosis and 
for variables entered in the model), the associations with younger age of onset 
and the negative dimension remained statistically significant (OR=0.95, 95% CI 
0.90-0.99) and (OR=1.17, 95% CI 1.01 -1.37) respectively. The association with 
gender was no longer significant (OR=1.047, 95% CI 0.49 -2.21).  
 
4.3.4 Additive effect of neurodevelopmental factors on 
treatment resistance at onset. 
 
There was an overall effect of the combined neurodevelopmental score on 
subsequent treatment resistance (OR=2.11; CI 1.29-3.47) as shown in Table 
4.3. With respect to the additive effect of neurodevelopmental factors, the risk of 
developing treatment resistance increased in a linear fashion with each 
additional neurodevelopmental factor: patients with 1 factor vs. patients with 2 
factors (OR=0.08, CI=0.01 – 0.73); patients with 2 factors vs. patients with 3 
factors (OR=0.33, CI=0.09 – 1.25) patients with 1 factor vs. patients with 3 
factors (OR=1.03, CI=0.34 – 3.09) (Figure 4.2).   
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4.3.5  The effect of gender on age of onset 
 
Females had significantly higher age of onset by approximately 4 years 
compared to males (t =2.91; p = 0.004). Subsequent analyses stratified by 
response, revealed no significant differences in the age of onset between male 
and female treatment resistant patients (mean (sd) age; males = 24.3 (6.6); 
females= 25.9 (6.1); t =0.89; p = 0.38), whereas the age of onset was 
significantly greater in female responders compared to male responders (mean 
(sd) age; males = 28.4 (8.7); females = 32.8 (11.2); t =2.78; p = 0.006).  Results 
are presented in Table 4.4.   Taking into consideration the potential influence of 
diagnostic type on the relationship of age at onset to response to treatment and 
gender (Meltzer et al., 1997), the analysis was repeated for patients with 
diagnosis of schizophrenia only, and similar results were obtained: no 
significant differences in the age of onset between male and female treatment 
resistant patients (mean (sd) age; males = 24.3 (5.2); females= 24.9 (6.6); t 
=0.34; p = 0.73), with female responders showing significantly greater age of 
onset relative to male responders (mean (sd) age; males = 28.1 (9.1); females= 
31.9 (10.3) (t =2.16; p = 0.03).  
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The risk of developing treatment resistance increased in an additive fashion 
with increasing number of factors present: patients with 3 factors present 
(earlier age of onset, higher NSS and negative symptoms) vs. patients with 1 
factor were significantly more likely to develop treatment resistance. Error 
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4.4 Discussion 
The principal finding of this study is that treatment resistance to antipsychotics 
manifests at the outset of illness in the great majority of patients.   Furthermore, 
to the best of my knowledge, this is the first study to investigate the predictive 
ability of putative neurodevelopmental markers specifically in patients who are 
persistently refractory to treatment right from the first presentation. Thus, the 
data demonstrated that the negative symptom dimension at a baseline and 
younger age of onset predispose to treatment resistance. Finally, the results 
suggest that the neurodevelopmental factors may have additive effect in 
increasing the risk of treatment resistance. 
 
4.4.1 Treatment resistance from the onset  
 
The finding that 61 patients, over 80% of treatment resistant patients, did not 
respond to antipsychotic medication from their first presentation indicates that in 
the majority, treatment resistance is an enduring trait of schizophrenic illness.  
Two first episode trials have similarly reported treatment resistance from the 
onset in a number of patients; Robinson et al., (1999) observed that 10 (8.5%) 
of their patients were unresponsive from their first episode despite intensive 
treatment that they received over one year follow up.  A similar percentage of 
first episode patients with schizophrenia who did not respond to medication and 
were “never well enough to be discharged,” during a 2 year follow-up, was 
reported in a previous first episode trial (MacMillan et al., 1986).  Kolakowska 
and colleagues (1985) in their relevant study of chronic schizophrenic patients 
retrospectively observed that the majority of their poor responders had shown 
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inadequate response throughout their illness and concluded that response to 
antipsychotics is determined by type, and not the stage of illness as proposed 
earlier (Bleuler M, 1978; Ciompi, 1980; Huber et al., 1975).  And, even some of 
the earliest psychiatric descriptions emphasize that the resistant type of illness 
may be already apparent in the initial phases of schizophrenia (Kraepelin, 
1919).  
 
However, a small number of patients (n=12; 17%) showed a good initial 
response to antipsychotics and developed resistance during the course of their 
illness, suggesting that there are two different types of treatment resistance; 
one form manifest at onset and the other that develops during the course of the 
illness, as previously advocated in the treatment resistance literature (Sheitman 
and Lieberman, 1998), although as evident in this work, the one that is always 
there and to which patients seem to be predestined, is more prevalent.   
   
4.4.2 Putative neurodevelopmental origin of treatment 
resistance from the onset 
 
Consistent with previous findings, younger age of onset and the negative 
symptom dimension were significant predictors of treatment resistance, even 
after the adjustment for diagnosis, DUP and gender.  However, the association 
with gender, after the adjustment, fell short of statistical significance. Abundant 
evidence has linked both negative symptoms and age of onset to treatment 
resistance Eaton et al., 1992; Scottish Schizophrenia Research Group.,1987, 
Kolakowska et al., 1985; Robinson et al., 1999; Kinon et al., 1993; Loebel et al., 
1992; Lindstrom, 1996; Meltzer et al., 2001).  It has been suggested that age of 
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onset is one of the key factors that may provide an aetiological clue to 
schizophrenia (DeLisi, 1992).  Studies in the late eighties documented that 
patients with a younger age of onset were more likely to have negative 
symptoms and cognitive impairments, (Johnstone et al.,1989) and additionally 
brain morphological defects (Crow et al., 1989)  than those with later age of 
onset.   These findings together with the observation that the higher the number 
of neurodevelopmental factors, the more likely it is that the patient will be 
resistant to treatment add weight to the idea that there is a neurodevelopmental 
aetiology to treatment resistance, in which disruptions during neurodevelopment 
have affected pathophysiology before the psychotic symptoms manifest. The 
findings here raise the possibility that it is TRS that is most compatible with the 
neurodevelopmental model proposed more than two decades ago (Meltzer et 
al.,2001; Murray et al.,1992; Murray and Lewis,1987; Murray et al.,1985; 
Weinberger,1987). Even Kraepelin, who advocated the neurodegenerative 
mechanism of illness, indicated that a in a proportion of ‘dementia praecox’ 
patients, who had low intellectual premorbid functioning, a neurodevelopmental 
origin was likely.  It could be that these patients are most akin to contemporary 
treatment resistant patients. 
 
4.4.3 Gender and age of first onset psychosis in relation to 
treatment response 
 
It has long been evident that schizophrenia tends to manifest earlier in men. 
The majority of studies have reported that the age of onset between 
schizophrenic men and women differs approximately by 3 to 5 years 
(Angermeyer and Kuhnz, 1988; Beratis et al.,1994; Faraone et al.,1994; 
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Goldstein et al.,1989; Hafner et al.,1992).  Similarly, in my present work, men in 
general had earlier age of onset by 4 years; however, the gender-age of onset 
relationship differed in relation to treatment response.  The age of onset in this 
sample is higher than that observed in other studies. This discrepancy is due to 
the fact that the AESOP study included all subjects who presented to the 
psychiatric services up to the age of 64, which is in contrast with most FEP 
studies that tended to use age 35 as an upper age limit.  The gender difference 
in age of onset may suggest that the association between early age of onset 
and treatment resistance is biased by male gender.  However, while the effect 
of gender on age at onset was obvious in responders, this effect disappears in 
TRS patients indicating that the age of onset is not gender-dependent and has 
direct influence on treatment resistance. These intriguing results replicate and 
confirm previous findings from the excellent study conducted by Meltzer and 
colleagues (2001) who were the first to address the issue of a gender effect on 
age at onset specifically in relation to treatment response, using stringent 
criteria for treatment resistance (Meltzer et al., 2001).  The authors concluded 
that these two subgroups of patients are premorbidly distinct, and that women 
with the younger age of onset are particularly at risk of developing treatment 
resistance.   
 
The later age of onset in female responders and more favorable course of 
illness could be explained, at least in part, by the antidopaminergic effect of 
natural oestrogen in women (Buckman and Peake, 1973). The protective effect 
of sex hormones specifically oestrogens, putatively mediated via reduction in 
dopaminergic transmission, was observed by Hafner and colleagues (1991), 
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who postulated that: “oestradiol might act as a protective modulator in 
schizophrenia by enhancing the vulnerability threshold for psychosis through 
the downward regulation of DA neurotransmission” (Hafner et al.,1991).   
Accordingly, with increasing age the oestrogen levels are reduced, which in turn 
will have less effect on reducing dopamine transmission and consequently at a 
later age, women may be at increased risk of developing a psychotic disorder 
brought on by modulation in dopamine receptor sensitivity (Angermeyer and 
Kuhnz, 1988; Seeman, 1981).  This is of particular significance for the finding 
that in treatment resistance the age of onset is not gender dependent i.e. 
younger age of onset irrespective of gender is a critical factor on developing 
treatment resistance. As demonstrated in Chapter 4 (Demjaha et al., 2012), the 
pathophysiology of treatment resistance does not appear to involve dopamine 
alterations, therefore oestrogens’ protective role in this condition is not relevant,  
or for as yet unknown reasons, dopamine-oestrogen interaction is impaired.  
Differential response to serotonergic challenge drugs among male and female 
patients with schizophrenia has been reported (Meltzer et al.,1993), and in 
addition, heterogeneity in central serotonergic sensitivity within the treatment 
resistant subgroup (Lindenmayer et al.,1997). In addition, these data 
demonstrate that it is the younger age of onset and not the gender that is 
instrumental in heralding treatment resistance, and reveal further that women of 
a younger age of onset are at particular risk of not responding to dopamine 
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4.4.4 Methodological considerations 
 
Although this study is of a longitudinal design and patients were 
comprehensively assessed and examined at their first presentation to services, 
with a substantial proportion re-interviewed (41.8%) at follow up, the case 
histories had to be reconstructed over the follow-up period to complete sections 
of the Life Chart including data on medication, compliance and 
psychopathology, which could have introduced information or recall bias.  
However, it has been demonstrated that the WHO Life Chart can be used to 
obtain reliable ratings (Susser et al., 2000).  In terms of symptomatology, 
however, as mentioned by Kolakowska et al., (1989), the tendency would be 
towards an overestimation of response, since patients who do not show 
significant behavioral disturbance, and particularly the ones with severe 
negative symptoms could often be rated by clinicians as “stable,” even when 
they are still symptomatic.  In all patients who were resistant to medication from 
the initiation of treatment rigorous examination of comprehensive medical 
records revealed that patients in this study have been persistently symptomatic. 
Another limitation is a small number of neurodevelopmental factors, specifically 
with regards to testing the additive value of these factors in generating 
treatment resistance.  Nevertheless, this is one of the largest and longest follow 
up studies examining schizophrenic patients from their first psychotic episode 
that specifically addresses neurodevelopmental predictors of specifically 
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Chapter 5 General Discussion   
 
5.1 Collective thesis findings  
The principal finding of the thesis (Chapter 3) indicates that the pathophysiology 
of patients with schizophrenia, who are resistant to dopamine blocking 
antipsychotics, is not marked by abnormal pre-synaptic striatal dopamine 
synthesis capacity, raising the possibility that treatment resistance is a 
neurobiologically distinct subtype of schizophrenia.  This is the first study in the 
field that, using the high resolution PET scanning, has measured in vivo 
presynaptic dopamine synthesis in specifically treatment resistant patients 
classified according to stringent criteria.  Due to the study’s cross-sectional 
design, it was not possible to determine whether normal dopamine levels 
predated the antipsychotic exposure.  It could be that antipsychotic medication 
reduces the initially high presynaptic dopamine levels without achieving 
symptomatic remission as postulated by Grunder et al., (2003), however, as 
shown in this work treatment does not normalize dopamine levels in responders 
that were significantly increased compared to those in treatment resistant 
patients.  Furthermore, the study in Chapter 4 revealed that over 80% of 
patients are persistently treatment resistant from the initiation of antipsychotic 
treatment.  Moreover, these persistently resistant patients tended to have more 
severe negative symptoms at baseline and younger age of onset, and 
moreover, were more likely to develop resistance, if more than one of these 
factors were present.  Finally, the finding that women whose schizophrenic 
illness manifests earlier are particularly at risk of becoming treatment resistant 
may add further support to the notion that dopamine may be normal at the 
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commencement of illness, and that other neurotransmitters may be instrumental 
or play a more prominent role in the neurobiology of treatment resistance, which 
precludes ooestrogen from exerting its protective effect as discussed.   
 
Taken together, the work in this thesis suggests that TRS is a distinct and 
enduring subtype of schizophrenic illness, one which, is probably 
neurodevelopmentally mediated, and perhaps characterized by different 
molecular mechanisms that do not lead to increased dopamine transmission.  
 
Integrating findings from this thesis with those derived from published literature 
(Chapter 1), a putative or preliminary model of predicting treatment resistance 
that integrates normal pre-synaptic dopamine levels and various indicators of 
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Figure 5.1 Putative model integrating factors that may predict treatment 








5.2 Scientific and clinical contribution of the thesis 
findings in the field of treatment resistance 
 
One of the main impediments to finding novel and effective treatments for 
incapacitating psychotic symptoms that in a considerable proportion of patients 
persist despite treatment is the present lack of understanding of the 
neurobiology of TRS, notwithstanding over 50 years of scientific work in the 
field. Not only has the neurobiology of treatment resistance remained 
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mysterious, but it has not been easy to predict who will initially not respond to 
treatment.  Work in this thesis illuminates understanding of the neurobiology of 
treatment resistance, which may subsequently inform new drug development. 
Furthermore, in combination with previous findings, it may alert clinicians to 
patients, early in their illness, who are more likely to be at risk of not responding 
to dopaminergic blockade, and encourage them to commence clozapine as 
early as possible, and thus prevent established and enduring treatment 
resistance in such a disabling condition as schizophrenia. 
 
5.2.1 Implications for the DA hypothesis 
 
Despite criticism and intense research efforts over the decades to deconstruct 
the complex pathophysiology of schizophrenia, DA hypothesis continues to 
remarkably thrive in a rapidly changing scientific milieu.  This is not entirely 
surprising, taking into account the fact that: a) the DA blocking antipsychotics 
are effective in a proportion of patients with schizophrenia, and b) psychogenic 
agents increase DA levels.  And indeed for the patients who are responsive to 
dopamine blockers, the hypothesis does hold true, or plays a role to an extent, 
but over the years failed to provide explanations for patients who remain 
treatment resistant despite guaranteed DA blockade. Direct confirmation in this 
thesis of the absence of hyperdopaminergia in patients with limited response to 
dopaminergic drugs, clarifies for the first time why since its genesis, the DA 
hypothesis could not account for the neurobiology of treatment resistance in 
schizophrenia. The findings provide support for other and distinct 
neurobiological mechanisms in this subgroup of patients that may involve 
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complex interactions of other neurotransmitters, as described in a following 
section. 
 
5.2.2 New insights into neurobiology of treatment resistance 
and implications for novel treatment approaches 
This thesis provides some of the first inklings into the pathophysiology of TRS, 
and may in part explain resistance to current dopamine blocking antipsychotics. 
Thus, the findings in Chapter 3 indicate that other molecular mechanisms, most 
probably involving glutamate and GABA, but possibly also other 
neurotransmitters, may be contributing to pathophysiology of treatment 
resistance. In particular, evidence that glutamate dysfunction may contribute to 
the pathophysiology of schizophrenia and the efficacy of clozapine in patients 
who have not responded to treatment with strong D2 antagonists suggests that 
changes in the glutamate system and its interaction with other neurotransmitters 
may be an important pathophysiological factor in this subgroup of patients. The 
importance of the glutamate system in treatment resistance has been 
substantiated by the effectiveness of lamotrigine, as an augmentation strategy 
in treating these patients, via inhibition of excessive glutamate transmission in 
the brain, (Tiihonen et al.,2003).  Most recent data preliminary show that 
treatment resistant patients, in the face of relatively normal striatal dopamine 
synthesis capacity, have elevated anterior cingulate cortex glutamate levels 
(Demjaha et al.,2013) indicating that glutamate is a logical new therapeutic 
target.  Recent meta-analytic work has demonstrated significant effects of 
glutamatergic agents, such as glycine/D-serine site antagonists, on negative 
symptoms (Tsai et al., 2010) that are generally resistant to dopamine blocking 
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antipsychotics.  In a view of complex interplay of neurotransmitters governing 
schizophrenia and particularly treatment resistance, another promising 
therapeutic approach is stimulation of GABA receptors to overcome 
glutamatergic deficits, which is yet to be tested in clinical trials (Kantrowitz, J.T., 
and Javitt,.2010). 
 
5.2.3 Contribution to the debate on neurodevelopmental versus 
neurodegenerative origin of treatment resistance   
 
The findings in Chapter 4 add weight to the notion that treatment resistance 
may be a stable and neurodevelopmentally marked phenotype of schizophrenic 
illness. Whilst there is an on-going debate in the field as to whether 
schizophrenia is of a neurodevelopmental or neurodegenerative origin, from this 
work it appears that treatment resistance is the schizophrenic subtype most 
compatible with neurodevelopmental model proposed in the early eighties 
(Murray and Lewis,1987; Murray et al.,1985, Weinberger,1987).  Even a century 
ago, although Kraepelin held that “dementia praecox,” is of a 
neurodegenerative nature, he importantly recognized a subtype of illness 
arising from neurodevelopmental disruption affecting patients with low 
intellectual premorbid functioning that may be akin to contemporary treatment 
resistant patients.  There is, however, a small proportion of patients identified in 
this work, who whilst they initially responded to medication, ultimately 
developed treatment resistance, which suggests that treatment resistance in 
schizophrenia is heterogeneous. Whether the development of treatment 
resistance in these patients is due to the effect of repeated exposure to 
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medication, dopamine sensitization, or the effect of neurodegeneration remains 
to be answered. 
 
The finding that patients with more severe negative symptoms and younger age 
of onset are most likely to be resistant adds further weight to existing evidence, 
and the presence of more than one of the neurodevelopmental factors renders 
patient more likely not to respond to treatment. 
 
5.3 Methodological issues   
Even though this work has started to unravel the enigma of mechanisms of 
TRS, the results should be considered in the context of methodological 
limitations that in some detail were discussed in respective chapters.   The main 
issue is that the cross-sectional design of the study did not permit me to 
determine whether these patients initially have high dopamine levels similar to 
those observed in their counterparts who show good response to medication, 
and then some neurochemical change in response to chronicity and exposure 
to various dopamine-blocking drugs occurs that results in normal dopamine 
levels in a context of persistent symptoms.  The fact that the majority of patients 
in the second thesis study have been resistant right from the onset of illness 
raises the possibility, albeit indirectly, that relatively normal dopamine levels 
predate exposure to antipsychotic treatment.  All patients in the first study had a 
continuous course of illness with no recorded periods of remission and the 
clinical records in most of our cases indicated that treatment resistant patients 
had shown poor response to treatment from the outset of illness.  However, 
since presynaptic dopamine levels have not been directly and prospectively 
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measured in the same sample, firm conclusions at this stage should not be 
drawn.   
 
Another issue is related to the choice and number of neurodevelopmental 
factors used to examine associations with TRS in my second study.  As 
discussed in Chapter 1, there is evidence that early age of onset, male 
gender and negative symptoms are good markers of poor outcome or TRS 
therefore, based on these findings, it was reasonable to hypothesize that these 
factors will be related to TRS. Due to limited and insufficient information on 
obstetric complications, family history, premorbid function and MPA, it has not 
been possible to test these important predictive factors in relation to TRS 
 
5.4 Future directions 
Establishing directly whether differences in the severity of dopamine dysfunction 
predate exposure to antipsychotics will require long-term prospective studies of 
therapeutic response in patients who are initially medication-naïve.  Similar 
work investigating dopamine synthesis capacity in first episode psychosis prior 
to starting antipsychotic medication and how this determines treatment 
response is currently underway (Howes et al., 2013).  Outstanding unanswered 
questions relate to other aspects of DA transmission such as DA release, or 
extra striatal DA transmission, in treatment resistance that would require more 
selective and specific tracers. 
 
Future studies, in addition, need to determine the mediating role of other 
neurotransmitters in the pathophysiology of treatment resistance.  As evident in 
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Carlsson’s and Grace’s work (Chapter 2.4 and Chapter 3), the interactions 
between different neurotransmitters are complex, and precise mechanisms of 
how and whether they affect the dopamine system needs to be clarified in new 
studies.  This will require the development of new radiotracers to investigate 
non-dopaminergic systems that would hopefully illuminate further the 
understanding of neurobiology of TRS. 
  
Further characterization of the important role of negative symptoms in predicting 
treatment resistance is also needed, which could have implications for both 
criteria for defining treatment resistance and treatment of these incapacitating 
symptoms. Most treatment resistance definitions have largely focused on 
persistent positive symptoms.  In view of the negative symptom significance for 
treatment resistance, consideration should be given to their inclusion, in 
addition to positive psychotic symptoms, in criteria for treatment resistance.  
Refractoriness of these symptoms represents a critical unmet treatment need, 
which has been highlighted by the National Institute of Mental Health (NIMH) 
initiative (Kirkpatrick et al., 2006). 
 
Overall, recognizing which patients are destined to show poor response to 
treatment (Figure 5.1) would prevent their unnecessary exposure to unwanted 
side effects of ineffective antipsychotics, and commencement of clozapine in 
the earliest stages of illness, which may halt the devastating effect of intractable 
and persistent psychopathology on patients’ lives. This is of particular 
importance for women with a younger age of schizophrenia onset, who are 
especially sensitive to antipsychotic induced hyperprolactinaemia, which may 
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lead to long-term endocrine disturbances (Smith et al., 2002).  Therefore, 
further research is needed to elucidate mechanisms governing treatment 
resistance specifically in young women and clarify the status of ooestrogens 
and its effect on dopamine synthesis in these patients. Finally, studies, 
examining all relevant neurodevelopmental factors documented in the published 
literature to date are required to contribute to developing a predictive model of 
treatment resistance. 
  
Nevertheless, the work emerging from this thesis provides a platform for these 
future studies, which may hopefully lead to a discovery of much needed new 
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Objective: Elevated presynaptic striatal
dopaminergic function is a robust feature
of schizophrenia. However, the relation-
ship between this dopamine abnormality
and the response to dopamine-blocking
antipsychotic treatments is unclear. The
authors tested the hypothesis that in
patients with schizophrenia the response
to antipsychotic treatment would be re-
lated to the severity of presynaptic dopa-
mine dysfunction, as indexed using [18F]-
DOPA uptake positron emission tomogra-
phy (PET).
Method: Twelve patients with treatment-
resistant schizophrenia, twelve patients
with schizophrenia who had responded to
antipsychotics, and twelve healthy volun-
teers matched for gender, age, ethnicity,
weight, and cigarette smoking underwent
[18F]-DOPA PET scanning. [18F]-DOPA in-
ﬂux rate constants (Ki
cer values) were mea-
sured in the striatum and its functional
subdivisions.
Results: Patients who had responded to
antipsychotic treatment showed signiﬁ-
cantly higher Ki
cer striatal values than did
patients with treatment-resistant illness
(effect size=1.11) and healthy volunteers
(effect size=1.12). The elevated [18F]-DOPA
uptake wasmostmarked in the associative
(effect size=1.31) and the limbic (effect
size=1.04) striatal subdivisions. There were
no signiﬁcant differences between pa-
tients with treatment-resistant illness and
healthy volunteers in the whole striatum
or any of its subdivisions.
Conclusions: In some patients with
schizophrenia, antipsychotic treatment
may be ineffective because they do not
exhibit the elevation in dopamine synthe-
sis capacity that is classically associated
with the disorder; this may reﬂect a differ-
ent underlying pathophysiology or a differ-
ential effect of antipsychotic treatment.
Am J Psychiatry Demjaha et al.; AiA:1–8
Between 20% and 35% of patients with schizophrenia
show only a limited response to antipsychotic treatment
(1). This treatment resistance is a major clinical problem,
impairing the lives of these patients.
The dopamine hypothesis of schizophrenia proposes
that dysregulated dopaminergic function underlies the
positive psychotic symptoms of the disorder (2). Support-
ing this hypothesis, eight radiolabeled DOPA positron
emission tomography (PET) studies have reported that
dopamine synthesis capacity is elevated in schizophrenia,
with effect sizes ranging from 0.63 to 1.89 (3). Furthermore,
elevated dopamine synthesis capacity predates the onset
of psychosis (4, 5) and progressively increases as patients
move from the prodromal phase to the ﬁrst episode of
illness (6). Other molecular imaging studies in schizophre-
nia indicate that both dopamine release and baseline
dopamine levels are elevated (7, 8).
There is substantial evidence that the efﬁcacy of
antipsychotic drugs is related to dopamine D2 receptor
blockade (9). All currently approved antipsychotic medi-
cations block dopamine receptors (10), and their relative
clinical potency closely parallels their binding and block-
ing afﬁnity for the dopamineD2 receptor subtype (11). PET
studies have demonstrated a signiﬁcant association
between striatal D2 occupancy and short-term clinical
response to antipsychotic treatment (12) and have in-
dicated that at least 50% occupancy of D2 receptors is
necessary to achieve clinical response (13). Wolkin et al.
(14) have investigated D2 receptor occupancy in relation to
treatment resistance in schizophrenia. They found almost
identical levels of striatal dopamine receptor occupancy in
patients who responded to antipsychotic treatment and
those with treatment-resistant illness, suggesting that while
adequate D2 blockade may be necessary for a therapeutic
response, it does not guarantee it.
Dopamine levels have also been linked to treatment
response. It has been shown that the higher the level of
striatal synaptic dopamine, the better the subsequent re-
sponse to antipsychotic treatment (7). However, to our
knowledge no study has examined dopamine synthesis
capacity speciﬁcally in relation to treatment resistance.
The limited data available suggest that patients who do
not respond to current dopamine-blocking treatments
may have a lower level of [18F]-DOPA uptake than those
who respond to dopaminergic blockers (7, 15). However, it
could also be argued that patients who do not respond to
antipsychotic treatment have an exceptionally hyperactive
dopaminergic system that is not blocked by current
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antipsychotics. We sought to address this issue by us-
ing [18F]-DOPA PET to compare dopamine synthesis ca-
pacity in patients who have shown a good response to
antipsychotic treatment with those who have shown a
poor response, as well as with healthy comparison
subjects.
Method
The study protocol was approved by the research ethics
committee of the Institute of Psychiatry, King’s College London,
and permission to administer radioactive substances was granted
by the Administration of Radioactive Substances Advisory
Committee, United Kingdom. All participants gave written in-
formed consent to participate after receiving a full description of
the study.
We recruited two groups of patients, deﬁned according to their
response to antipsychotic treatment. All met DSM-IV criteria for
schizophrenia, paranoid subtype, determined by using OPCRIT
(the Operational Criteria Checklist) (16). The group with
treatment-resistant illness (treatment-resistant group; N=14)
comprised patients who met modiﬁed Kane criteria for treat-
ment resistance (17). All of these patients had previously received
at least two sequential antipsychotic trials, each of at least 4
weeks’ duration at a daily dose of 400–600 mg of chlorpromazine
equivalents, but continued to have persistent psychotic symp-
toms, which was deﬁned as having a rating of at least moderate
severity on one or more items on the positive symptom subscale
of the Positive and Negative Syndrome Scale (PANSS) (18),
having a total PANSS score $75 (19), and having a score ,59 on
the Global Assessment of Functioning (corresponding to at least
moderate functional impairment) (20). The group of patients
who responded to antipsychotic treatment (responder group;
N=12) comprised patients who met the Remission in Schizo-
phrenia Working Group criteria for treatment remission (21).
These patients scored #3 on all items of the PANSS (correspond-
ing to mild severity or no symptoms) and had not experienced
a symptomatic relapse in the 6 months prior to the study. All
patients were recruited from the South London and Maudsley
NHS Trust. A group of healthy comparison subjects (N=12) with
no previous or current history of psychiatric illness (as assessed
by the Structured Clinical Interview for DSM-IV Axis I Disorders
and the Structured Clinical Interview for DSM-IV Personality
Disorders) and no family history of psychosis were recruited
through advertisements in the press. The groups were matched
for age, gender, ethnicity, weight, and smoking. Patients in the
treatment-resistant and responder groups were matched, in
addition, for duration of illness and for antipsychotic dosage (in
chlorpromazine equivalents).
All patients were receiving antipsychotic medication other
than clozapine at the time of scanning. Two patients in the
treatment-resistant group had previously been treated with
clozapine, but it had been discontinued because of side effects
without reaching therapeutic blood levels. Adherence to medi-
cation was determined by measuring antipsychotic drug serum
levels and by reviewing pharmacy and medical records. Patients
were excluded if there was evidence of nonadherence at any
point in the 6 months prior to the scan or if serum levels were
not at adequate levels. Exclusion criteria for all groups were
pregnancy (all women received a pregnancy test prior to
scanning), contraindication to imaging, history of neurological
or active medical illness or head injury, or substance abuse
or dependence. All patients received a urine drug screen
prior to scanning and were excluded if it was positive for illicit
substances.
One patient was excluded from the treatment-resistant group
because he did not complete the scanning, and one patient in
the treatment-resistant group withdrew from the study. The data
analysis was therefore restricted to 12 patients in the treatment-
resistant group, 12 patients in the responder group, and 12
healthy volunteers.
PET Protocol
Participants were instructed to fast and to refrain from caffeine,
tobacco, and alcohol for at least 12 hours before scanning. One
hour before the start of each scan, all subjects received 150 mg p.o.
of carbidopa, a peripheral aromatic acid decarboxylase inhibitor,
and 400 mg p.o. of entacapone, a peripheral catechol-O-
methyltransferase inhibitor, to increase speciﬁc signal detection,
as these compounds reduce the formation of radioactively la-
beled metabolites that may cross the blood-brain barrier and
thus confound the measurements.
PET imaging data were acquired on a Siemens/CTI ECAT HR+
962 PET scanner (Erlangen, Germany) in three-dimensional
mode, with an axial ﬁeld of view of 15.5 cm. Participants
were positioned in the scanner with the orbitomeatal line parallel
to the transaxial plane of the tomograph. Head position was
monitored via laser crosshairs and video camera. The initial
transmission scan was followed by administration of approxi-
mately 180 MBq of the radiotracer [18F]-DOPA, a radioactive
analog of l-dopa, as a bolus intravenous injection over 30
seconds. Emission data were obtained as 26 frames of increasing
duration over 90 minutes (comprising a 30-second background
frame, four 60-second frames, three 120-second frames, three
180-second frames, and ﬁnally ﬁfteen 300-second frames). In
addition, structural MRI was conducted to exclude intracranial
abnormalities. No gross abnormalities were detected in any
participant in a review by a neuroradiologist blind to the subject
group.
Image Analysis
Both automated region-of-interest and voxel-based statistical
image analyses with the cerebellum as reference region were
performed to examine striatal [18F]-DOPA uptake, as previously
described by our group (4–6). The region-of-interest analysis
(performed by A.D.) included the whole striatum and its
associative, limbic, and sensorimotor subregions, delineated as
described by Martinez et al. (22). These functional striatal
subdivisions reﬂect the differential striatal-cortical connectivity
and the functional organization of the striatum. The limbic
striatum, anatomically equivalent to the ventral striatum, re-
ceives input from limbic structures such as the hippocampus and
amygdala and includes the nucleus accumbens. The associative
striatum comprises the precommissural dorsal caudate, precom-
missural dorsal putamen, and postcommissural caudate and re-
ceives input from associative cortical regions, including the
dorsolateral prefrontal cortex. The sensorimotor striatum in-
cludes the postcommissural putamen and receives project-
ions predominantly from motor and premotor areas (22). The
region-of-interest map thus comprised the whole striatum, its
subdivisions, and the cerebellum, deﬁned using a probabilistic
atlas.
To correct for head movement, the nonattenuated dynamic
image was denoised and realigned frame-to-frame to a single
reference frame acquired 7 minutes after [18F]-DOPA injection.
Next, the transformation parameters were applied to the cor-
responding attenuation-corrected frames, and the realigned
frames were summated to create a movement-corrected dy-
namic image ready for analysis. The region-of-interest map
was then normalized together with an [18F]-DOPA template to
each individual PET summation image using SPM5 (www.ﬁl.ion.
ucl.ac.uk/spm), which allows region of interest to be placed
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automatically and without observer bias on individual [18F]-
DOPA PET dynamic images. A Patlak graphical analysis was used
to calculate striatal [18F]-DOPA inﬂux rate constants (Ki
cer
values) (23) to index striatal dopamine synthesis capacity relative
to uptake in the reference region (the cerebellum) for left and
right sides combined.
Voxel-based statistical image analysis was performed to in-
dependently conﬁrm the results derived from region-of-interest
analysis and determine whether there were subregional differ-
ences. Parametric maps of the inﬂux rate constants for [18F]-DOPA
were constructed from movement-corrected images by using
a wavelet-based kinetic modeling approach that increases the
signal-to-noise ratio without signiﬁcantly affecting resolution (see
Howes et al. [4]). After normalization of the parametric images,
statistical analyses were performed using SPM5, restricted to the
striatum using a mask, to examine differences between groups.
The results presented were analyzed with correction for multiple
comparisons (p,0.05, family-wise error rate) and, in a further
sensitivity analysis, without correction.
Statistical Analysis
We conducted preliminary tests to explore homogeneity of
variance, regression slopes, normality, and reliable measurements
of covariates. The Kolmogorov-Smirnov test conﬁrmed that the
data were normally distributed. To determine whether there was
an effect of group on striatal Ki
cer values and on demographic,
striatal volume, and clinical data, analysis of variance and in-
dependent t tests were performed as appropriate. When there
were signiﬁcant group effects, planned independent t tests were
performed using Bonferroni correction for multiple comparisons
to examine differences in Ki
cer values between groups. To assess
whether the effect was inﬂuenced by medication, an additional
analysis of covariance was performed with daily medication dose
(in chlorpromazine equivalents) added as a covariate. The
independent variable was group, and the dependent variables
were the Ki values for the striatum and its three subdivisions. A
two-tailed signiﬁcance threshold of 0.05 was used throughout.
Results
Demographic and clinical characteristics are presented
in Table 1, and antipsychotic use is summarized in Table 2.
No between-group differences were observed for age,
gender, ethnicity, weight, radiation dose received, ciga-
rette smoking, duration of illness, ormedication dosage. In
addition, there were no differences across the groups for
the whole striatal volume or any of its subdivisions.
Figure 1 shows the mean dopamine synthesis capacity
for the three groups. The analysis of variance identiﬁed
a statistically signiﬁcant effect of group on Ki
cer values for
the whole striatum (F=5.4, df=2, 33, p=0.01) and for each of
its associative (F=6.7, df=2, 33, p=0.004), limbic (F=4.0,
df=2, 33, p=0.03), and sensorimotor subdivisions (F=3.4,
df=2, 33, p=0.05). Mean Ki
cer values are listed in Table 3.
Because one of the patients in the responder group had
particularly high Ki
cer values, we repeated the analysis
with that subject excluded. The group effect remained
signiﬁcant for the whole striatum (F=4.2, df=2, 32, p=0.02)
and its associative subdivision (F=6.4, df=2, 32, p=0.005),
but not the other striatal subdivisions.
To assess the effect of antipsychoticmedication, the anal-
ysis was repeated with the addition of medication dose
(in chlorpromazine equivalents) at the time of scanning
as a covariate. The effects of group on Ki
cer values from the
whole striatum (F=7.2, df=1, 22, p=0.01) and the associative
(F=10.2, df=1, 22, p=0.005) and limbic (F=6.4, df=1, 22,
p=0.02) subdivisions remained signiﬁcant, but there was
no longer a signiﬁcant difference in the sensorimotor
subdivision.
Between-Group Comparisons
Treatment-resistant versus responder group. After adjust-
ment for multiple comparisons, Ki
cer values were signiﬁ-
cantly greater in the responder group than in the treatment-
resistant group in the whole striatum (p=0.02, corrected;
effect size=1.11) and the associative (p=0.008, corrected;
effect size=1.31) and limbic subdivisions (p=0.03, corrected;
effect size=1.04). There was no signiﬁcant difference in the
sensorimotor subdivision.
Greater Ki
cer values in the responder group than in the
treatment-resistant group were also observed in the cor-
responding voxel-based analysis, with a peak in the head
of the caudate (p=0.039), which lies within the associative
subdivision of the striatum (Figure 2). The difference was
signiﬁcant at p,0.05, corrected for multiple comparisons
using the family-wise error rate. The treatment-resistant
group . responder group contrast showed no signiﬁcant
differences, even at an uncorrected statistical threshold
(p,0.05, uncorrected).
Responder group versus healthy volunteers. Ki
cer values
were signiﬁcantly elevated in the responder group compared
with the healthy volunteer group, after multiple comparison
adjustments, in the whole striatum (p=0.02, corrected; effect
size=1.12) and the associative subdivision (p=0.01, corrected;
effect size=1.24), but not in the limbic or sensorimotor
subdivisions. Similarly, the voxel-based analysis revealed
signiﬁcantly greater Ki
cer values in the responder group
compared with the healthy volunteer group, with a peak in
the caudate (p=0.037, corrected at the family-wise error rate).
The voxel-based contrast of the healthy volunteers with the
responder group showed no signiﬁcant differences, even at
an uncorrected threshold (p,0.05 uncorrected).
Treatment-resistant group versus healthy volunteers. There
was no signiﬁcant difference in mean striatal Ki
cer values
between the treatment-resistant group and the healthy
volunteers, in the whole striatum or its subdivisions. This
was conﬁrmed with the subsequent voxel-based analysis
for the contrast of treatment-resistant group . healthy
volunteer group and for the contrast of the healthy
volunteer group . treatment-resistant group, even at an
uncorrected threshold (p,0.05, uncorrected).
Discussion
To our knowledge, this is the ﬁrst study to provide direct
evidence that dopamine synthesis capacity in schizophre-
nia is lower in patients with treatment-resistant illness
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than in those who show a good response to antipsychotic
medication. This suggests that treatments that involve the
blockade of dopamine receptorsmaybeeffective in patients
who have an elevation of dopamine synthesis capacity but
less useful inpatients inwhomdopamine synthesis capacity
is relatively normal.
Limitations
One potential limitation of our study is that the patients
were chronically medicated, which could have inﬂuenced
presynaptic dopamine synthesis capacity (24). The two
patient groups were matched for both the current dosage
of medication and the total duration of treatment. The
mean daily dose was higher in the treatment-resistant
group (reﬂecting their poor response to treatment), but
the difference in dose was not statistically signiﬁcant, and
group differences in Ki
cer values remained signiﬁcant after
covarying for dose. Another potential limitation is that our
patients received various types of antipsychotic drugs that
could have differentially affected dopamine synthesis.
However, the groups were relatively well matched in terms
of generation and type of antipsychotics (see Table 2). Two
of our patients, one in the treatment-resistant group and
the other in the responder group, were taking amisulpride,
which at dosages lower than 200 mg daily may increase
dopamine transmission via a preferential blockade of
presynaptic D2-like autoreceptors (25). However, as these
two patients received much higher dosages—800 mg and
600mg daily, respectively—than the level for a preferential
presynaptic action and were in different groups, it is
unlikely that our results were affected. Only one of our
patients (in the responder group) was taking aripiprazole,
which has the unique property of being a partial dopamine
receptor agonist (25). Theoretically, partial agonists should
reduce dopamine synthesis capacity, reﬂected in a lower
the Ki
cer value, although in practice little net effect has
been observed during chronic aripiprazole administration
in rats (26). As the aripiprazole-treated patient was in the
responder group, a reduction in Ki
cer value would reduce
rather than account for the group differences we observed
TABLE 1. Demographic and Clinical Characteristics of Patients With Treatment-Resistant Schizophrenia, Treatment








Mean SD Mean SD Mean SD
Age (years) 45.7 9.8 44.0 11.9 44.2 8.9
Weight (kg) 80.9 19.2 83.0 20.7 80.9 23.3
Radioactivity injected (MBq) 180.0 5.5 183.6 4.3 183.4 5.6
Speciﬁc activity (GBq/mmol) 0.025 0.017 0.033 0.015 0.035 0.019
Duration of illness (years) 16.1 8.6 16.2 10.1
Medication dosage (mg/day
chlorpromazine equivalents)
396.1 157.5 283.9 159.14
Positive and Negative Syndrome Scale
Total score 104.3 10.6 50.7 5.8
Positive symptom score 26.2 3.8 11.9 2.4
Global Assessment of Functioning score 47.5 3.9 67.5 4.5
Whole striatal volume (mm3) 15,590.9 1,675.2 16,424.1 1,818.9 16,773.6 1,870.1
Associative striatal volume (mm3) 9,644.0 1,165.5 10,185.0 1,164.1 10,005.0 1,768.2
Limbic striatal volume (mm3) 1,953.1 262.3 1,965.5 348.0 2,013.1 269.3
Sensorimotor striatal volume (mm3) 4,260.2 928.6 4,189.6 513.5 4,394.4 459.6
N % N % N %
Male 5 41.6 6 50.0 5 41.6
Smoker 3 25.0 4 33.3 3 25.0
Ethnicity
White 5 41.6 4 33.3 6 50.0
Black 6 50.0 7 58.3 4 33.3
Asian 1 8.3 1 8.3 2 16.7
a No signiﬁcant differences between groups on any variable.
TABLE 2. Antipsychotic Use in Patients With Treatment-








Antipsychotic N % N %
Olanzapine 3 25.0 2 16.7
Quetiapine 2 16.7 1 8.3
Amisulpride 1 8.3 1 8.3
Risperidone 1 8.3 0 0.0
Risperidone depot 2 16.7 3 25.0
Aripiprazole 0 0.0 1 8.3
Chlorpromazine 1 8.3 0 0.0
Zuclopenthixol decanoate 1 8.3 3 25.0
Flupenthixol decanoate 1 8.3 1 8.3
a No signiﬁcant differences between groups.
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between the responder and treatment-resistant groups.
Furthermore, as the Ki
cer values for this individual were
similar to the mean Ki
cer value for the group, it is unlikely
that including the aripiprazole-treated individual had
a major effect on the overall results.
As the group sizes were relatively modest, the possibility
that the absence of differences in dopamine synthesis
capacity between the treatment-resistant group and the
healthy volunteers could reﬂect limited statistical power
should be also considered. However, data from previous
studies in schizophrenia suggest that the effect size for the
elevation in dopamine synthesis capacity measured using
the same PET protocol is relatively large (.1) (4, 27), and
a formal power calculation indicated that a sample size of
12 per group had 80% power to detect an effect size of
.0.7, using a two-group two-sided t test and a signiﬁcance
threshold of 0.05.
Presynaptic Dopamine Synthesis Capacity
in Treatment-Resistant Schizophrenia
The lack of an elevation in presynaptic striatal dopamine
synthesis capacity in patients with treatment-resistant
illness could provide an explanation for the ineffectiveness
of antipsychotic treatment in this group. Our ﬁndings are
in agreement with studies of plasma homovanillic acid in
patients prior to treatment with antipsychotics: levels were
higher in the responder group than in the treatment-
resistant group (15). Furthermore, Abi-Dargham et al. (7)
FIGURE 1. Mean Dopamine Synthesis Capacity for the Whole Striatum in Patients With Treatment-Resistant Schizophrenia,







































a The treatment-resistant group showed signiﬁcantly lower dopamine synthesis capacity than the treatment responders (p=0.02, corrected for
multiple comparisons). There were no signiﬁcant differences between treatment-resistant patients and healthy volunteers. Error bars indicate
standard deviation.
TABLE 3. Comparison of Mean Presynaptic Striatal Ki
cer Values Between Patients With Treatment-Resistant Schizophrenia,







Brain Structure Mean SD Mean SD Mean SD F (df=2,33) p
Whole striatum 1.331022 0.1431022 1.431022 0.1831022 1.331022 0.1431022 5.38 0.01
Associative striatum 1.231022 0.1431022 1.431022 0.1531022 1.231022 0.1431022 6.71 0.004
Limbic striatum 1.331022 0.1731022 1.531022 0.2331022 1.331022 0.1731022 4.02 0.03
Sensorimotor striatum 1.431022 0.231022 1.631022 0.2431022 1.431022 0.1531022 3.38 0.05
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found that higher synaptic dopamine levels, as indexed by
D2 receptor occupancy, were associated with a better
response to antipsychotic treatment. There is evidence
from animal studies that chronic treatment with
dopamine-blocking antipsychotics induces D2 receptor
up-regulation, which can reduce the efﬁcacy of antipsy-
chotic treatment andmay lead to breakthrough dopamine
supersensitivity (28, 29). Whether these elevated D2
receptors may then affect dopamine synthesis in patients
with treatment-resistant illness is not entirely clear. Our
study was cross-sectional and therefore cannot determine
whether presynaptic dopamine synthesis capacity was
normal in patients in the treatment-resistant group at the
onset of their illness, or whether it was initially abnormal
but then some change occurred so that the persistent
psychotic symptoms were no longer related to a striatal
dopamine excess. Kolakowska et al. (30) observed that in
most of their patients with treatment-resistant illness, the
response to antipsychotic treatment had been insufﬁcient
throughout the illness, which led them to conclude that
the treatment response was linked to the type rather than
the stage of schizophrenia. Establishing whether differ-
ences in the severity of dopamine dysfunction predate
exposure to antipsychotics will require long-term pro-
spective studies of therapeutic response in patients who
are initially medication naive.
Higher Presynaptic Dopamine Synthesis Capacity
in Responders
We observed signiﬁcantly higher presynaptic dopamine
synthesis capacity in patients who showed a good re-
sponse to antipsychotics, with the strongest effect ob-
served in the associative subdivision of the striatum,
consistent with previous evidence (4, 5, 31). While the
elevation in the responder group is consistent with some
previous PET studies in chronic patients (27, 32), there are
conﬂicting reports from other studies in chronic stable
patients with schizophrenia that found no signiﬁcant
dopamine elevation (33, 34). These studies, however, did
not distinguish speciﬁcally between patients with a good
response to antipsychotics and those with treatment-
resistant illness, which may explain the discrepancy in
results. Thus, the studies that found a dopamine elevation
could have included predominantly responders, and those
that reported no elevation may have included more
patients with treatment-resistant illness.
One tentative explanation for the paradoxically high
dopamine synthesis capacity in the face of relative
symptomatic remission could be that in the context of
chronic exposure to D2 receptor blockade, these patients
do not have enhanced transmission, because of the
ambient postsynaptic D2 blockade. However, it is not
clear whether antipsychotic drugs do normalize dopamine
synthesis capacity. In one study (35) acute treatment was
found to increase dopamine synthesis capacity, although in
another study (36) no overall effect was observed. On the
other hand, Gründer et al. (37) have reported that longer-
term antipsychotic treatment reduces presynaptic dopa-
mine synthesis capacity, and preclinical studies (38, 39)
have shown that antipsychotics induce delayed depolar-
ization block of presynaptic dopamine neurons, an effect
that is more rapidly induced in a rat schizophrenia model
showing increased dopamine neuron activity than in wild-
type rats. However, the Gründer et al. study (37) did not
include healthy volunteers; thus, while antipsychotics
reduced dopamine synthesis capacity, it remains unknown
whether antipsychotic treatment normalized dopamine
synthesis or not. Our study and some other studies (4, 27),
although not all (34), involving antipsychotic-treated
patients suggest that dopamine synthesis capacity is not
completely normalized by antipsychotic treatment. Finally,
the effect size seen in our responder group approximates
that observed in previous studies of dopamine synthesis
capacity in schizophrenia, including those involving
medication-free or medication-naive patients (4). Thus,
overall, these ﬁndings suggest that medication does not
explain the elevation seen in the responder group.
Conclusions
These data indicate that schizophrenia patients whose
illness is resistant to antipsychotic treatment have relatively
normal levels of dopamine synthesis capacity, compared
with levels in patients whose symptoms respond to
treatment. This suggests either that patients with
treatment-resistant illness start with a different underlying
FIGURE 2. Greater Striatal Dopamine Synthesis Capacity in
Schizophrenia Treatment Responders Relative to Patients
With Treatment-Resistant Illnessa
a The images show increased dopamine synthesis capacity in
responders (N=12) relative to patients with treatment-resistant
illness (N=12). The most signiﬁcant increase was in the head of the
caudate nucleus (p=0.039, corrected at the family-wise error rate).
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pathophysiology or that antipsychotics have an effect on
their dopamine synthesis capacity, albeit one that does not
reduce symptoms. Since our studywas cross-sectional and
comprised a small sample of medicated patients, our
results require replication, ideally in prospective studies
of large samples of antipsychotic-naive patients. Future
studies need to determine the involvement of other
neurotransmitters. In particular, evidence that glutamate
dysfunction may contribute to the pathophysiology of
schizophrenia and to the efﬁcacy of clozapine in patients
who have not responded to treatment with stronger D2
antagonists suggests that changes in the glutamate system
and its interactionwith other neurotransmittersmay be an
important factor in this subgroup (40).
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